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1. INTRODUCTION AND QUESTION 
1.1. MICROBIOTA IN THE GASTROINTESTINALTRACT AND THEIR IMPACT 
ON HEALTH 
The composition of the gut flora differs from human to human and is therefore like a 
fingerprint unique. Postnatal, microorganisms colonize the gastrointestinal tract. The 
highly acidic stomach fluids are a chemical barrier for microorganisms and therefore 
the stomach holds low bacterial counts (Madigan and Martinko 2006). Mainly 
facultative anaerobes like Lactobacilli, Streptococci and yeasts are present. The 
bacterial load increases in the small intestine, especially that of the Enterobacteria, 
Lactobacilli and Streptococci which are facultative anaerobes yet anaerobes like 
Bacteroides, Bifidobacteria and Clostridia are also predominant. The colon has 
enormous numbers of bacteria as well as the greatest diversity of all. Dominant are 
strict anaerobes like Bacteroides spp., Clostridia, Ruminococcus spp., Butyrovibrio 
spp., Fusobacterium spp., Eubacterium spp., Peptostreptococcus, Bifidobacterium 
spp., Atopobium spp., and Pepptococci.  Facultative anaerobes also occur but in 
smaller amounts like, Lactobacilli, Enterococci, Streptococci and Enterobacteriaceae 
(Rastall 2004). The diversity of bacteria in the human colon is very high but until now 
it has not been possible to detect all of them. Currently, millions of microbial species 
exist that are not cultivated (Achtman and Wagner 2008). 
 
Archaea, Eukarya and Bacteria are the main domains which are present in the 
human gut, bacteria making up the largest amount (Backhed, Ley et al. 2005). Within 
the domain bacteria, Firmicutes and Bacteroidetes are the most abundant phyla in 
the gut. Firmicutes are butyrate producing bacteria and among others, belong to the 
Clostridia Class. In small amounts, occur Proteobacteria, Actinobacteria, 
Fusobacterua and Verrucomicrobia phylas (Eckburg, Bik et al. 2005). Clostridium 
coccoides group (clostridial cluster XIVa), Clostridium leptum subgroup (clostridial 
cluster IV) and Bacteroides-Prevotella group are quantitatively dominant bacteria in 
the faeces of healthy individuals (Sokol, Lay et al. 2008). 
About one third of faeces are made up of bacteria. The bacteria which live in the 
lumen of the large intestine are continuously washed out with the flow of the material 
and replaced through new growth (Madigan and Martinko 2006). 
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Figure I. Key physiologic and microbiological features of the gut. 
Relative concentrations of bacteria and the PH at various locations within the adult gut are also noted. 
Cfu = colony forming unit. 
(DiBaise, Zhang et al. 2008) 
 
 
 
With the development of methods for identifying gut microflora they have noted that 
about 1012 microorganisms per millimetre of luminal content colonize the 
gastrointestinal tract in an adult human. The diversity is very high; about 500-1000 
different bacterial species are detected. Meanwhile it is not possible to verify all 
occurring bacteria. Current studies suppose that the numbers are actually much 
higher, from up to 15000 to 36000 species of bacteria. Several studies have shown 
that the lower portion of the gastrointestinal tract has a higher bacterial count with 
basically anaerobic bacteria and the upper portion with lower counts is primarily 
colonized with aerobic bacteria (DiBaise, Zhang et al. 2008). 
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Figure II.  Major Bacteria and Archaea Phyla and Genera Found in the Human Gut Microbiotaa. 
a Prokaryotic phyla were identified by using an alignment of the 18,348-sequence dataset from (Ley, 
Backhed et al. 2005). 
b Not related to any known genera.  
(DiBaise, Zhang et al. 2008) 
 
 
 
The latest study from Qin et al. led to the conclusion that a ‘core’ microbiome exists, 
which hypothesizes against previous study results. To analyse the microbial 
communites, investigators conducted the experiment by metagenomic sequencing 
which is an alternative to rRNA sequencing used in precedent studies (Qin, Li et al.; 
Riesenfeld, Schloss et al. 2004; Tringe and Rubin 2005; von Mering, Hugenholtz et 
al. 2007). Qin et al. genetically investigated faecal samples from 124 European 
adults. Subjects were either healthy, obese or affected by Inflammatory bowel 
disease (IBD). Investigators could identify 3.3 million genes and additionally found 
out that 38% of the total gene pool was equal in each individual. The subjects who 
were affected from Inflammatory bowel disease had 25% fewer common genes. This 
is consistent with previous studies who have already noticed that these individuals 
have a lowered bacterial diversity (Qin, Li et al.; Manichanh, Rigottier-Gois et al. 
2006). To quantify, 57 bacterial species were present in ≥ 90% and 75 of the 
bacterial species were present in ≥50% and at least 18 species occurred in all 
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individuals. Like in previous studies Bacteroides and Firmicutes made up the highest 
amount (Qin, Li et al.). 
A “microbiome” is the collective genome of microorganisms present in humans. The 
microbiome encodes 100-fold more unique genes than our own genome. The 
genomes of the microbiome possess traits of which humans have not evolved (Gill, 
Pop et al. 2006). 
The ‘core human microbiome’ represents the set of genes occurring in all or in the 
vast majority of humans. Genes which are present in a smaller percentage of 
humans belong to the ‘variable human microbiome’. The ‘variable human 
microbiome’ is influenced by the host itself. The environment in which the host is 
exposed, the diet habits and other lifestyle factors of the host, the genotype of the 
host, the physiological status of the host, the host’s state of health, as well as 
transients organisms occurring in the host, all are factors which are decisive of  the 
‘variable microbiome’ (Turnbaugh, Ley et al. 2007).  
 
 
 
 
Figure III. The concept of a core human microbiome. 
(Turnbaugh, Ley et al. 2007) 
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The Microbiota – BIRTH 
At birth, the colon of an infant is sterile. The first colonization is influenced by the 
bacterial load of the environment as well as the mode of delivery and nutrition are 
deciding. Bifidobacteria and Lactobacilli are dominant in breastfed infants and have a 
positive impact. In Formula-fed infants the ratio of Bifidobacteria to Enterobacteria is 
1:1 whereas in breastfed infants the ratio is 10:1 (Harmsen, Wildeboer-Veloo et al. 
2000; Roy, Kien et al. 2006). Oligosaccharides are the most important factor for the 
intestinal flora and make up the third largest component after lactose in the human 
milk (Coppa, Bruni et al. 2004; Roy, Kien et al. 2006). 15-25% of the 
Oligosaccharides are acidic (Boehm, Jelinek et al. 2004). They are resistant to 
digestion, reach the colon, where the bacterial fermentation and the production of 
short chain fatty acids (SCFA) take place. This process promotes the growth of 
selective bacteria, especially the Bifidogenic flora (Coppa, Bruni et al. 2004; Roy, 
Kien et al. 2006). 
SCFA: 
• Are a substantial source of energy  
• Have a trophic effect of monocytes 
• Enhance the re-absorption of water and sodium 
(Coppa, Bruni et al. 2004; Roy, Kien et al. 2006) 
 
In preterm infants the flora is alike to that of formula-fed infants, especially in the first 
days of life. The Enterobacteria occur in higher amounts and the Bifidobacteria 
emerge later as in full-term formula fed infants (Magne, Suau et al. 2005; Roy, Kien 
et al. 2006). Healthy infants are colonized by Bifidobacterium longum, breve and 
lactis (Sakata, Tonooka et al. 2005; Isolauri, Kalliomaki et al. 2008), whereas 
disturbance in the composition of Bifidobacterium microbiota is associated with 
increased amount of Bifidobacterium adolescentis as well as Clostridia (Kalliomaki, 
Kirjavainen et al. 2001; Kirjavainen, Arvola et al. 2002; Isolauri, Kalliomaki et al. 
2008). 
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1.1.1. Microbiota and Metabolic Functions 
The gut microbiome has beneficial effects for its host. It is responsible for (1) 
maintaining homeostasis, (2) removing pathogens by competing about nutrients and 
epithelial sites, (3) producing antimicrobial compounds, (4) boosting gut barrier 
function (5) having immune-modulatory effects (Sheil, Shanahan et al. 2007), and in 
addition (6) is included in  epithelial turnover, (7) gastrointestinal motility and (8) drug 
metabolism.  
Furthermore the gut microbiome has metabolic functions like (8) synthesising 
micronutrients, (9) fermenting indigestible food substances, (10) is involved in the 
absorption of certain electrolytes and trace minerals and (11) responsibility for the 
break down of dietary toxins and carcinogens (DiBaise, Zhang et al. 2008) (12) 
protecting the epithelium against cell injury (13) involvement  in regulating fat storage 
and (14) influencing angiogenesis in the intestine (Eckburg, Bik et al. 2005). 
 
The affection of growth and differentiation of enterocytes and colonocytes is possible 
through the production of short chain fatty acids, generated by indigestible 
components which are fermented by the bacteria in the gut (DiBaise, Zhang et al. 
2008). Bacteria have the ability to ferment indigestible substances and thereby 
extract energy. There is a syntrophic interaction between bacteria and Archaea. 
Bacteria generate due to the fermentation of short chain fatty acids, organic acids 
and gases like H2 and CO2. An accumulation of H2 inhibits the NADH dehydrogenase 
and therefore energy extraction is impossible. For that reason Archaea have the 
potential to remove H2 by utilizing it for methanogenesis (Samuel and Gordon 2006; 
DiBaise, Zhang et al. 2008). 
 
1.1.2. Groups of Microbiota 
The majority of bacteria in the gut are anaerobia. There is a differentiation between 
aerobic, anaerobic and microaerophil bacteria. For living conditions aerob bacteria 
need oxygen, whereas anaerob bacteria can survive without oxygen. Microaerophil 
represents that these bacteria grow in a milieu with reduced oxygen. 
Furthermore there is a classification between obligate and transient microorganisms 
(Beckmann and Rüffer 2000). Beside the obligate flora, transient organisms occur, 
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sometimes in high amounts, and sometimes in such low amounts that they are not 
detectable (Zwielehner, Liszt et al. 2009). Obligate organisms are resistant and 
stable and have important functions in the gut while transient organisms are exogen 
organisms which pass the gut and do not have under healthy conditions a chance to 
damage the gut. Another differentiation is based on the metabolic activity of the 
microorganisms. 
In addition, a classification between microorganisms with lipolytic activity, 
microorganisms with proteolytic activity and microorganisms with sacharolytic activity 
exists (Beckmann and Rüffer 2000). 
 
Bacteria, Eukaryota and Archaea are the present life forms, although Bacteria clearly 
dominate (DiBaise, Zhang et al. 2008). Currently nine bacterial phyla are known to 
colonize the human gastrointestinal tract of which Firmicutes, Bacteroidetes and 
Actinobacteria are dominant (Backhed, Ley et al. 2005). The human gut microbiome 
is individually different and therefore it is very difficult to define an overall model 
(Rajilic-Stojanovic, Smidt et al. 2007). In general a high diversity is desirable 
(McCann 2000). Nonetheless ‘core’ species exist in the majority of humans (Dore 
2007; Zwielehner, Liszt et al. 2009).  In this paper, the focus will be centred on 
Lactobacilli, several Clostridia Clusters, Bacteroides and Bifidobacteria because 
these are the major bacteria which are most likely associated with dysfunctions of the 
gut. 
 
1.1.2.1. Firmicutes 
Gram positive bacteria of the Firmicutes phylum seem to have specific enzymatic 
enzymes which might play a crucial role in obesity (Turnbaugh, Hamady et al. 2009). 
Patients with Morbus Crohn have a significant reduction of Firmicutes qualitatively as 
well as quantitatively in their faeces (Sokol, Lay et al. 2008). In patients with 
Ulcerative Colitis Firmicutes, the amount is as well reduced (Sokol, Lepage et al. 
2006; Andoh, Sakata et al. 2007; Sokol, Lay et al. 2008). 
 
 
 
 8   
1.1.2.1.1. Lactobacillus spp.: 
Lactobacilli are mikroaerophil which means that they grow under oxygen reduced 
conditions. The major species in the gut are Lactobacillus acidophilus, Lactobacillus 
salvarius, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus brevis and 
Lactobacillus cellobiosus. 
Lactobacilli occur on plants, and are applied in the food industry as starter cultures.  
Lactobacilli belong to the obligate flora of the small and the large intestine, the mouth 
and the vagina. In healthy individuals constitutes the bacterial counts from 105 to 107 
/g faeces (Beckmann and Rüffer 2000). 
Lactobacilli produce antimicrobial agents and have therefore a positive impact on 
health. Furthermore they occupy receptors sites, compete about nutrients and about 
space (Rastall 2004) and as a result of SCFA generation, they acidify the milieu and 
inhibit thereby the colonisation of pathogens (Guarner 2005). The growth of 
Lactobacilli can be stimulated due to prebiotics like inulin and fructo-oligosaccharides 
(Van Loo 2004). 
Lactobacilli seem to increase in their amount in obese individuals and therefore they 
might play an important role in weight gain (Armougom, Henry et al. 2009); due to 
their function in food conversion (Khan, Raoult et al. 2007). A reduced amount of 
Lactobacilli in IBD patients is observed as well. In patients with Ulcerative Colitis 
(UC) the number of Lactobacilli in the faeces seems to be reduced (Bullock, Booth et 
al. 2004; Sokol, Lay et al. 2008). In ulcerated tissues the number of Lactobacilli was 
reduced in comparison to non ulcerated tissues (Zhang, Liu et al. 2007; Armougom, 
Henry et al. 2009). Furthermore, in patients with diarrhea the amount of Lactobacilli 
seems to be significantly reduced (Sullivan, Edlund et al. 2001) . 
 
1.1.2.1.2. Clostridium Cluster IV and XIV 
Clostridial clusters IV [Clostridium leptum subgroup] and XIVa [Clostridium coccoides 
group] contain bacteria which are butyrate producers. Eubacterium, Roseburia, 
Faecalibacterium and Coprococcus are the main species (Pryde, Duncan et al. 
2002). Clostridium Cluster IV influences beneficial functions like nutrient absorption, 
generation of short chain fatty acids and epithelial cell maturation and maintenance 
(Woodmansey 2007; Zwielehner, Liszt et al. 2009). Faecalibacterium prausnitzii is 
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part of the most abundant bacteria in the human faeces and belongs to Clostridia 
Cluster IV (Suau, Rochet et al. 2001). 
E. rectale-C. coccoides group belongs to the clostridia cluster XIV. These are the 
main butyrate producing bacteria in the distal colon. Butyric acid is the product after 
the fermentation of carbohydrates and is used as an energy source for the epithelial 
cells. Through the reduction of these bacteria it might be possible that not as much 
energy can be harvested and therefore, this could positively influence weight loss. 
Nevertheless, butyrate has beneficial effects such as better satiety. For that reason, 
other more complex mechanisms related to the fatty acid metabolism may be linked 
to Firmicutes and Clostridium clusters with obesity (Nadal, Santacruz et al. 2009). 
 
Clostridia Cluster IV is significantly reduced in amount as well as diversity in the 
elderly in comparison to young individuals (Zwielehner, Liszt et al. 2009) especially 
Faecalibacterium prausnitzii (Bartosch, Fite et al. 2004). Patients with Crohn´s 
disease (CD) seem to have a decline in the amount of Clostridium Cluster IV in 
faeces (Scanlan, Shanahan et al. 2006). In addition the amount of Faecalibacterium 
prausnitzii was markedly reduced on the mucosal surfaces of CD patients (Bartosch, 
Fite et al. 2004; Frank, St Amand et al. 2007) On the contrary Clostridial Cluster XIVa 
is reduced in its amount in the mucosa of patients with UC (Swidsinski, Weber et al. 
2005). In ulcerated tissue the number of  Clostridial Cluster IV seems to be reduced 
in comparison to non ulcerated tissue (Zhang, Liu et al. 2007). 
 
1.1.2.1.3. Clostridium Cluster II 
Clostridium hystolyticum is part of the Clostridia Cluster II. This bacterium is highly 
proteolytic and produces acetate. Increased acetate amounts promote gut 
colonisation and stimulate lipid synthesis. Furthermore, Clostridium hystolyticum 
produces cytotoxic proteases which may have a pathogen effect for cells and tissue 
(Nadal, Santacruz et al. 2009). 
 
1.1.2.1.4. Clostridium Cluster XI 
C.lituseburense counts to the clostridia cluster XI. This cluster is heterogeneous and 
contains opportunistic pathogens such as Clostridium difficile. Clostridium difficile 
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and Clostridium hystolyticum may influence the potential virulence of the gut 
microbiota in obese patients (Nadal, Santacruz et al. 2009). Several studies 
concluded that Clostridium difficile occurs especially in children who develop atopic 
diseases (Bottcher, Nordin et al. 2000; Bjorksten, Sepp et al. 2001; Kalliomaki, 
Kirjavainen et al. 2001; Penders, Thijs et al. 2007; Sjogren, Jenmalm et al. 2009). In 
addition Clostridium difficile is very often the causative agent for antibiotic induced 
diarrhea (Bartlett 1987). Two toxins are produced by Clostridium difficile which are 
responsible for the mucosal damage and the inflammation in the colon (Hogenauer, 
Hammer et al. 1998). 
 
1.1.2.2. Bacteroidetes 
1.1.2.2.1. Bacteroides 
Belong to the anaerob bacteria and are most important for colonial resistance 
because quantitatively they make up the largest amount. In the large intestine 108-
1010 bacterial counts/g occur in healthy individuals (Beckmann and Rüffer 2000). 
Bacteroidetes are included in nutrient absorption, in the short chain fatty acid 
production and further in epithelial cell maturation and maintenance (Woodmansey 
2007). Bacteroides produce propionate which inhibits lipid synthesis of acetate and 
this may enhance a lean phenotype (Nadal, Santacruz et al. 2009). 
High variations between individuals occur in the species Bacteroidetes, even though 
Bacteroidetes thetaiotaomicron occurred in each human individual (Layton, McKay et 
al. 2006).  Several studies pointed that a decline of Bacteroides and an increase of 
Firmicutes is associated with obesity. Much more astonishing was the conclusion that 
Bacteroidetes thetaiotaomicron seem to play an important factor in host adiposity 
(Ley, Turnbaugh et al. 2006; Samuel and Gordon 2006). Not less than 8% of its 
genome is dedicated for carbohydrate metabolism and functions in Bacteroidetes 
thetaiotaomicron (Xu, Bjursell et al. 2003). Bacteroides thetaiotaomicron is highly 
efficient in glycan metabolism whereby indigestible substances are metabolized and 
used as energy source (Comstock and Coyne 2003; DiBaise, Zhang et al. 2008). 
The impact of Bacteroides in the development of atopic diseases is not clear until 
now. While Bjorksten et al. concluded that allergic infants had at the age of one year 
old a decreased colonisation with Bacteroides (Bjorksten, Sepp et al. 2001; 
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Songjinda, Nakayama et al. 2007); Songjinda et al. gathered that children who 
developed allergy by their second birthday had significant increased amounts of 
Bacteroidaceae in comparison to non-allergic subjects. These conflicting results may 
be caused by different sampling ages and also is a result due to sampling before and 
after weaning (Songjinda, Nakayama et al. 2007).  
Bacteroides thetaiotaomicron regulates intracellular downstream of TLR signalling 
and NF-κB activation, and thereby reduces inflammation (Kelly, Campbell et al. 2004; 
Songjinda, Nakayama et al. 2007), Bacteroides fragilis stimulates increased induction 
of TH2 cells which leads to increased generation of inflammatory cytokines 
(Odamaki, Xiao et al. 2007; Songjinda, Nakayama et al. 2007). The amount of fecal 
bacteria, especially of the Bacteroides-Prevotella-Porphyromonas group, seems to 
be reduced during acute diarrhea in contrast to periods of a normal health state 
(Balamurugan, Janardhan et al. 2008). 
 
1.1.2.3. Actinobacteria 
1.1.2.3.1. Bifidobacterium spp.: 
Bifidobacteria live under anaerob conditions. In the gut Bifidobacterium infantis, 
Bifidobacterium breve, Bifidobacterium adolescentis, Bifidobacterium longum, 
Bifidobacterium bifidum are common bacteria. Mainly they occur in the large intestine 
and in small amounts in the small intestine. The amount in healthy individuals is 
between 108-1010 bacterial counts /g faces (Beckmann and Rüffer 2000). 
Bifidobacteria seem to be the most crucial bacterium in terms of health (Gibson and 
Roberfroid 1995). At least 8% in the genome of Bifidobacterium longum are 
responsible for carbohydrate transport and metabolism functions (Xu, Bjursell et al. 
2003). Furthermore, through acidification with SCFA, competing for nutrients, 
secretion of antimicrobial components and stimulation of the immune system the 
colonization of pathogens is inhibited (Guarner 2005). Several studies proved the 
effect of Bifidobacteria on enhanced barrier function of the gut epithelium 
(Zwielehner, Liszt et al. 2009). 
The growth of Bifidobacteria can be enhanced with prebiotics like inulin or fructo-
oligosaccharides (Kolida and Gibson 2007). Due to produced SCFA the growth of 
Bifidobacteria is stimulated (Roy, Kien et al. 2006). 
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Several studies have proven that the amount, as well as the diversity of 
Bifidobacteria is reduced in elderly in comparison to young individuals (Zwielehner, 
Liszt et al. 2009). The amount of Bifidobacteria in the epithelium seems to be much 
lower in UC patients than in healthy controls (Mylonaki, Rayment et al. 2005). 
Bifidobacteria might also have a protective role in development of atopic diseases. 
Nevertheless do we have to keep in mind, that different Bifidobacterium species have 
different functions (Apajalahti, Kettunen et al. 2003), and that allergic children have 
other Bifidobacteria species than healthy children (He, Ouwehand et al. 2001; 
Ouwehand, Isolauri et al. 2001; Penders, Stobberingh et al. 2007). While 
Bifidobacterium adolescentis occurs in higher amounts in allergic children, 
Bifidobacterium catenulatum and longum seem to be characteristic for healthy infants 
(He, Ouwehand et al. 2001; Ouwehand, Isolauri et al. 2001; Stsepetova, Sepp et al. 
2007). 
Generally the assumption exists that a low amount of Bifidobacteria in early 
childhood is associated with allergy development (Bjorksten, Naaber et al. 1999; 
Kalliomaki, Kirjavainen et al. 2001; Stsepetova, Sepp et al. 2007). In the case of 
diarrhea, the amount of Bifidobacteria seems to be reduced (Sullivan, Edlund et al. 
2001). 
 
1.1.2.4. Archaea 
Methanobrevibacter smithii is hydrogen consuming methanogen and the most 
occurring phylotype of Archaea. Due to the Archaeal methanogenesis the 
fermentation of polysaccharides is facilitated because methanogenesis prevents the 
generation of hydrogen and other reaction end products. Thereby bacteria have the 
possibility to produce more acetate and butyrate, which seem to be energy sources 
for epithelial cells. For this reason, the assumption exists that Archaea especially that 
of Methanobreviacter smithii, might be an important factor in energy extraction and 
hence in gaining weight (DiBaise, Zhang et al. 2008). 
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1.1.3. Molecular Mechanisms in the Epithel 
The normal intestinal immune--regulation 
The mucosa associated immune system is an independent differentiated 
immunological compartment. The main function of the intestinal mucosa associated 
immune system of the gut (GALT) is to inhibit the invasion of infectious and toxic 
pathogens in the intestinal lumen. We find the most immune cells of the body in the 
mucosa associated immune system (Stange 2004). 
Gut associated immune system 
Unspecific factors: 
• Acidity of the gastric juice 
• Microbicidal function from digestive secrets 
• Productive peristaltic 
• Mucin secretion 
(Beckmann and Rüffer 2000) 
Specific factors: 
There is a high density of immune cells in the submucosa of the gut. T-Lymphocytes 
are regulator- and effector-cells which induce the immunity by producing secretoric 
IgA. Due to the activity of T-Lymphocytes antigen components of the diet can not 
lead to a systemic immune response (oral tolerance). On the one hand, T-
lymphocytes colonize as intraepithelial lymphocytes the mucosa of the gut and the 
lamina propria; and on the other hand the lymphoid tissue, the peyer´s patches. 
In addition to B and T cells, macrophages and dendritic cells occur in the lamina 
propria. These cells are responsible for processing and subsequently presenting 
antigens. Furthermore they can provide lysosomale enzymes and set oxygen 
radicals free, which can remove tissue and eliminate microorganisms (Beckmann 
and Rüffer 2000). 
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1.1.4. Probiotics and Prebiotics generally 
Some microbes in the gastrointestinal tract have beneficial functions such as 
producing nutrients, absorbing peptides and vitamins; on the contrary others produce 
toxins or compete with the host for common substrates (Torrallardona, Harris et al. 
1996; Murry, Lewis et al. 1997). Administration with probiotics could prevent the 
overgrowth of pathogens an thereby have a possible impact on health (Drago, 
Gismondo et al. 1997). 
Viable microbes can have an effect on health. However the composition of microbiota 
varies in each individual; therefore it is necessary to attune administration with 
probiotics for each individual. In doing so, it may be possible to improve health and 
prevent diseases. Microbiota ferment complex nutrients into simple sugars, short 
chain fatty acids and other nutrients; and thereby enable the absorption of these 
substances. The microbiota produces folic acid and the vitamins K, and B12 which 
are important in the bile acid metabolism and recirculation. The microbiota 
furthermore is essential in transforming carcinogens like N-nitroso compounds and 
heterocyclic amines. The activation of bioactive compounds is likewise possible (Mai 
and Draganov 2009). 
Common probiotics are among Lactobacilli and Bifidobacteria, Streptococcus, 
Enterococcus, non-pathogenic E.coli and Saccharomyces boulardii (Shanahan 
2001). 
 
1.1.4.1. Probiotics Definition 
The FAO and WHO defined probiotics in 2001 as “Live microorganisms which when 
administered in adequate amounts confer a health benefit on the host” (Bergonzelli, 
Blum et al. 2005). 
In Europe, the International Life Science Institute (ILSI) defines a probiotic as “a 
viable microbial food supplement which beneficially influences the health of the host”.  
The efficacy and safety of probiotics for each strain and each product must be 
scientifically proven (Kalliomaki, Salminen et al. 2008). 
 
 15   
1.1.4.2. Requirements on Probiotics 
Certain criteria have to be fulfilled by bacteria before they can be established as a 
probiotic. Firstly, it must be of human origin and secondly, they must be generally 
regarded as safe (GRAS). A probiotic must have the ability to reach the 
gastrointestinal tract in adequate amounts so it can unfold its impact. Therefore it has 
to fulfil special criteria, such as, after the uptake it has to pass the stomach and the 
passage of the small intestine where thirdly it has to be resistant against bile and 
acid. How well the impact of a probiotic is, is fourthly dependent on the adherence to 
intestinal cells and fifthly on it persistence in the gut for some time.  A colonisation of 
a probiotic is not required however persistence during the therapy is eligible (Dunne, 
O'Mahony et al. 2001; Sheil, Shanahan et al. 2007). Sixthly, it has to have the ability 
to produce antimicrobial substances, seventhly it must be antagonistic against 
pathogenic bacteria and finally it must have the ability to modulate the immune 
response (Sheil, Shanahan et al. 2007). 
1.1.4.3. Beneficial effects of Probiotics 
• Alleviation of lactose intolerance 
• Reduction of gastrointestinal infections or even prevention of them 
• Suppress cancer 
• The concentrations of plasma cholesterol is reduced which leads to a 
decrease of the risk for heart disease 
• Nutrients are better digested and therefore have a higher value 
(Sheil, Shanahan et al. 2007) 
 
1.1.4.4. Functions of Probiotics: 
(1) Improve gut barrier function, 
(2) Adhere on the mucosal surface 
(3) Prevent the binding of pathogens  
(4) Produce bacterocins 
(5) Modulate inflammatory response 
(6) Alleviate visceral hypersensitivity  
(7) Ferment nutrients and thereby acidify the colon 
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(8) Support the stability of the colonic microbiota. 
(Spiller 2008) 
 
1.1.4.5. Prebiotics Definition 
Prebiotics are defined as “nondigested food ingredients that artificially affect the host 
by selectively stimulating the growth or activity of one or a number of bacteria in the 
colon that can improve the host’s health” (Gibson and Roberfroid 1995).  
 
The distinction of dietary fibers is between soluble and insoluble fibers. Soluble fibers 
are completely fermented by the bacteria whereas insoluble fibers are nearly entirely 
excreted with the stool and fermentation proceeds in just small amounts (Asp 1995; 
Wong, de Souza et al. 2006). 
1.1.4.6. Functions of Prebiotics 
Dietary fibers slow the absorbance rate and increase the stool bulk. Furthermore 
soluble fibers slow the transit, stimulate the growth of commensal bacteria and due to 
their fermentation, short chain fatty acids are generated which affect the cholesterol 
metabolism (Cummings and Englyst 1995), cause an increased amount of SCFA 
leads to stimulation of adipogenesis and an increased leptin production may be a 
result. Due to a decreased synthesis and secretion of very low density lipoproteins 
(VLDL), SCFA have a hypocholesterolemic effect (Roy, Kien et al. 2006). 
 
1.1.4.7. Modern Molecular Findings 
The action of probiotics is strain and species specific. To achieve appropriate effects 
the right choice of organisms is therefore important. Further essays about the 
mechanisms of probiotics are necessary to better understand the effects of 
probiotics. Until now investigators have found that probiotics alter gut microbial 
diversity, have an affect of intestinal barrier function, modulate the immune response 
and induce the development of T regulatory cells and dendritic cells. Until now the 
knowhow about the host microbe crosstalk which initiates the process is too small 
(Reiff and Kelly 2009). 
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1.1.4.7.1. Secretion of Bacteriocins 
Hydrogen peroxide, organic acids, Diacetyl, Bacteriocins and Bacteriocins molecules 
are some of the products which are generated by probiotics and which have an 
antimicrobial effect in vitro (Ouwehand, Kirjavainen et al. 1999).  Nevertheless, in 
vivo none of these products have been proven to have an impact on health (Rastall, 
Gibson et al. 2005). 
 
Probiotics have antagonistic direct and indirect effects against pathogenic germs.  
Direct:  
One direct impact is the germ-killing lactic acid which is produced by Lactobacillus. 
Other microorganisms produce specific bacteriocines and other antimicrobial 
substances. Saccharomyces boullardii has the ability to destroy the toxins produced 
by Clostridium difficile due to its proteolytic activity. 
E.coli Nissle 1917 produces two different antagonistic active microcines. These 
microcines destroy the pathogen and proinflammatory Enterobacteria. These 
bacteria are responsible for acute inflammatory attacks in inflammatory bowel 
diseases. Therefore it may have a positive impact on chronic inflammatory bowel 
disease. 
The synthesis of bacteriocines is not automatic; it is administered by environmental 
conditions. The Quorum sensing is a cellular communication between bacteria where 
bacteria detect the population density. At a specific quantity of bacteria, the Quorum 
sensing causes the secretion of secondary metabolic products. Quorum sensing 
regulates alongside the bacteriocine production the production of biofilm, sporulation, 
symbioses and virulence. A further antimicrobial function is the occupation of 
probiotics of the mucus in the gut-epithelium so that pathogen germs do not have the 
possibility to colonise (Schulze, Sonnenborn et al. 2008). 
Indirect: 
Probiotics stimulate the mucin –gen expression and therefore enforce the amount of 
mucus which leads to a handicap for the interaction of pathogenic germs. 
E.coli Nissle 1917 has also indirect functions. It secretes diffusible signal-substances 
which have an impact on Enterobacteria by reducing the permeability for invasive 
diarrhoea inducing bacteria. Furthermore probiotics stimulate the bodies’ defensin-
production. Defensins are antimicrobial peptides. In patients with chronic 
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inflammatory bowel disease, the Defensin production is reduced, which leads to the 
conclusion that probiotics may have a positive impact (Schulze, Sonnenborn et al. 
2008). 
 
1.1.4.7.2. Immunmodulatory Actions 
Probiotics modulate the immunmodulatory actions either by altering the resident 
bacteria in the gut, or by enforcing the gut barrier function which is followed by a 
diminished potential for bacteria to activate the immune system. Moreover probiotics 
have an anti-inflammatory effect by stimulation of regulatory T-cells (Spiller 2008). 
E.coli Nissle 1917, L.-casei-, L.-rhamnosus-, L.-plantarum-, L.-gasseri- and L.-
acidophilus- strains possess significant immune-modulatory and anti-inflammatory 
functions. Lactobacilli allure macrophages and induce a modulation of the cytokine 
expression and the maturation of surface markers in dendritic cells (Schulze, 
Sonnenborn et al. 2008). In an experiment, healthy volunteers were treated with 
L.rhamnosus. Results showed that in peripheral blood mononuclear cells, an 
increase in IL-10 secretion and a decrease in TNF, IL-6 and interferon secretion 
appeared. Similar results arose in an experiment with atopic children after 
administration with L. rhamnosus. Other studies showed that VSL#3 increased a 
marker in Treg cells (Spiller 2008). 
Administration with VSL#3 inhibited expression of inflammatory Th1 cells, reduced 
pro-inflammatory Il-12 generation and elevated anti-inflammatory IL10 in isolated 
dendritic cells of blood and intestine from humans. A Reduction of IL-10 in IL-10KO 
mice proceeded also because of treatment with VSL#3. Treatment with 
Bifidobacterium longum lowered the secretion of pro-inflammatory TNF-α and IL-8. 
Furthermore a colonic biopsy of inflamed mucosa in Ulcerative colitis patients 
showed that Bifidobacterium longum achieved a reduction of NF-κB positive lamina 
propria mononuclear cells. The probiotic LGG has the ability to reduce intestinal 
epithelial apoptosis in C57BLJ mice. The induction of IL-10 dependent T regulatory 
cells which expresses TGF-β is controlled by VSL#3 treatment in chemically induced 
IBD. Bifidobacterium infantis 35624 induced a Treg expression and hindered NF-κB 
activation by pathogens. Lactobacillus acidophilus also induces Treg cells and 
expresses TGF-β. Gut tolerance can be promoted by probiotics but further 
investigation of the mechanism are needed (Reiff and Kelly 2009). 
 19   
1.1.4.7.3. Mucosal Adherence + Inhibition of Pathogenic Bacteria Adherence 
A competition of nutrients and space between the different bacterial strains is present 
in the gut. Lactobacillus spp. has been shown to reduce the growth of the 
invasiveness and adherence of enterotoxigenic E.coli in the epithelial. B.longum and 
E.coli Nissle 1917 have shown similar effects (Spiller 2008). In vitro it’s proven that 
probiotics can avoid the adhesion of pathogens such as E.coli, Salmonella enterica 
serotype Typhimuriium on the epithelial cells (Gill 2003). The supposed function 
behind this inhibition might be the competition of receptors, or the mucin production 
which is enforced due to probiotics (Mack, Michail et al. 1999; Lee and Puong 2002).  
 
1.1.4.7.4. Enhanced Barrier Function of Epithelium 
An experiment was conducted with IBD patients with pouchitis who stayed in 
remission because of antibiotic administration. Patients received VSL#3 which led to 
an increase of bacteria and a reduction of fungal diversity compared with the control 
group. An increase of mucosal barrier function leads to reduced translocation of 
bacteria and therefore the ability of pathogenic bacteria to attach to the gut mucosa is 
hindered. Probiotics may up-regulate expression of tight junctions like defensins, 
mucins or proteins. Barrier function is further up regulated by VSL#3 and 
Lactobacillus fermentum because of up-regulation of human β defensin 2. 
Administration with VSL#3 increased mucin gene expression and excretion in colonic 
epithelial cells. LGG leads to an increase in thickness of the mucosal mucus layer 
and a decrease of apoptotic cells in the gastric mucosa. L.acidophilus leads to an 
increased production of mucosal components and pro-inflammatory cytokines IL-8, 
IL-1β, and TNF-α in colonic epithelial cells. This up-regulation decreases the 
attachment capacities of E.coli O157:H7. Bifidobacterium lactis prevents an increase 
of epithelial permeability and protects tight junctions in Caco-2 cells. Administration 
with lactic acid bacteria decreased colonic permeability in IBS patients (Reiff and 
Kelly 2009). 
 
There is a bacterial epithelial crosstalk between bacteria of the gut and the cells of 
the epithelium which enables the exchange of signal-substances. The cells of the 
epithelium are important for the infection defence in the gut by detecting 
microorganisms. These cells are part of the gut associated immune system. The cells 
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of the epithelium posses pattern recognition receptors which have the ability to 
identify typical microbial structures and interact with them. Pattern recognition 
receptors signal the interaction between cytoplasm-membrane and microorganisms 
in the inside of the epithelium cell, where henceforward through signal cascades in 
the cell nucleus the transcription of inflammatory genes initiates.  
There upon a release of messengers takes place which attracts the immune cells 
residing behind the epithelium film. These immune cells can now act on the place of 
the inflammation and can fend the infection. Furthermore the epithelium cells contain 
intracellular agents NOD-receptors  (Nucleotide Oligomerization Domain) which have 
an impact on the inflammation cascade (Schulze, Sonnenborn et al. 2008). 
 
Studies demonstrated that an application of Lactobacilli, Bifidobacteria and E.coli 
Nissle 1917 strengthens or rather regenerate the mucosa barrier. Gastro-intestinal 
diseases like celiac disease or inflammatory bowel disease are among others 
characterized by a defective barrier of the gut (Schulze, Sonnenborn et al. 2008). 
Probiotics like VSL#3 and L.plantarum 299v do have a positive effect on barrier 
function (Spiller 2008). 
 
1.1.4.7.5. Acidification of the Colon through Nutrient Fermentation 
Probiotics have the potential to ferment unabsorbed polysaccharides and thereby 
generate short chain fatty acids. Lactic acid is one of them leading to acidification of 
the colon. The acidic milieu enables some bacteria to flourish while the growth of 
others is inhibited. Administration with L.plantarum leads to an ascent of acetic, 
propionic and butyric acid accompanied by an increase of Bifidobacteria spp. and 
Lactobacillus spp. and a decrease of Clostridia spp (Spiller 2008). 
 
1.1.4.7.5.1. Short Chain Fatty Acid Production 
Short chain fatty acids emerge out of bacterial fermentation in the colon. Substrates 
are polysaccharides, oligosaccharides, protein, peptides, and glycoprotein 
precursors. Short chain fatty acids are organic fatty acids which are made up out of 1 
to 6 carbon atoms. The abundance of produced short chain fatty acids is in 
dependence of (1) the species and amount of microflora in the colon, (2) the 
concentration of substrat and (3) the gut transit time. Besides SCFA, H2 and CO2 are 
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the end products after fermentation. The absorption of SCFA proceeds in the colon 
and is connected to an easier sodium absorption and bicarbonate excretion. (Wong, 
de Souza et al. 2006). 60-70% of the energy needs of colonocytes are supplied by 
SCFA and 10% of energy needs of the body are covered. Through an acidification 
with SCFA Bifidobacteria, Lactobacilli can inhibit the growth of potential pathogens. 
Other effects of Bifidobacteria and Lactobacilli which prevent an increase of 
pathogenic bacteria are that they compete for nutrients and for colonization sites. 
Furthermore Bifidobacteria and Lactobacilli enhance the immune system and secrete 
antimicrobial molecules. Through the increase of these bacteria a reduction of 
potential pathogenic bacteria would be the conclusion (Roy, Kien et al. 2006).  
 
Figure IV. Overall scheme of nutrients and carbohydrates (CHO) in particular, in their transit 
through the GI tract, their fermentation to short chain fatty acids (SCFA), and their fecal 
excretion. 
(Roy, Kien et al. 2006) 
 
 
 
Butyrate, acetate and propionate are the main short chain fatty acids in the colon. 
The molar ratio of short chain fatty acid production is approximately 60:20:20 
(Acetate: Propionate: Butyrate) (Cummings, Hill et al. 1979; Wong, de Souza et al. 
2006). Usually the ratio is constant, nevertheless dietary changes can influence the 
production and absorption of short chain fatty acids (Wong, de Souza et al. 2006). 
Acetate: is the main SCFA in the colon of humans and especially pectin is a major 
source (Kien, Schmitz-Brown et al. 2006; Roy, Kien et al. 2006). Acetate is 
fundamental for muscle heart and brain cells. Additionally it is the primary substrate 
for cholesterol generation.  But the hypothesis exists, that it’s substrate dependent, 
whether SCFA induces or prevents cholesterol generation. Lactulose for example 
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increased cholesterol synthesis whereas viscous fibers like psyllium are not as 
fermentable and reduce serum lipids (Wong, de Souza et al. 2006). 
Propionate: In some studies a positive impact on cholesterol levels was assessed. 
In small amounts it has butyrate impact on proliferation and differentiation of 
colonocytes (Topping and Clifton 2001; Roy, Kien et al. 2006). Propionate can be an 
inhibitor of gluconeogenesis but also a substrate. The propionate metabolism in 
humans is less well understood. Polyfructans like Inulin are used for Type 2 diabetes 
mellitus and hyperlipidemia because they decrease the acetate: propionate ratio 
which leads to a cholesterol reduction. The absorption of propionate is easier than 
the absorption of acetate in the human colon(Wong, de Souza et al. 2006). 
Butyrate: is the major colonocyte fuel. It induces proliferation and differentiation of 
cells. It is prevention for tumours because it induces growth arrest, differentiation and 
apoptosis in colorectal and polyp cell lines.  Main sources are starch, oat and wheat 
bran (Kien, Schmitz-Brown et al. 2006; Roy, Kien et al. 2006). Butyrate is the energy 
source for colonocytes. 70-90% of butyrate is metabolized by colonocytes and it also 
plays an important role in proliferation and differentiation, and apoptosis of cells 
(Wong, de Souza et al. 2006). Furthermore it has an anti-inflammatory effect 
because it inhibits the activation of NF-κB and therefore reduces generation of 
proinflammatory cytokines. The use of butyrate is preferred compared to propionate 
and acetate (Pryde, Duncan et al. 2002). 
 
Functions of short chain fatty acids: 
(1) Are a nutrient supply for colonocytes 
(2) Lead to a decline of the ph in the colon and intracellular which leads to 
changes in the gut microbiota, to a declined solubility of bile acids, to an 
increased mineral absorption especially calcium and decreased ammonia 
absorption.  
(3) Modulate functions of ion transport 
(4) Regulate proliferation, differentiation and gene expression 
(Wong, de Souza et al. 2006) 
(5) Through up-regulation of Toll like receptors they stimulate the bacterial-
epithelial crosstalk (Forchielli and Walker 2005). 
(6) Cytokines like Interleukin 10 and INF-γ are up-regulated (Roller, Rechkemmer 
et al. 2004). 
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(7) Increased production of polymeric IgA (Roller, Rechkemmer et al. 2004; 
Zapolska-Downar, Siennicka et al. 2004). 
(8) Before prebiotics convert to SCFA they interfere the attachment of bacteria to 
microvillus glycoconjugates (Forchielli and Walker 2005).  
(Roy, Kien et al. 2006) 
 
1.1.5. Analytical Methods 
Since the 1990s, culture independent methods which opened up new vistas are 
common. Nevertheless 70% of the gut microbiota remained unexplored due to the 
utilization of culture based techniques. The culture independent methods identify 
bacteria via the ribosomal RNA molecules (16s rRNA) which are small subunits of 
sequences. Variable and hypervariable regions compose of the 16s rRNA gene 
which enable designing probes or primers to detect the entire domain, a phylum, a 
group, a genus or just a single species of a bacterium (Sokol, Seksik et al. 2009). 
 
The faeces are often used for analysis to assess the intestinal microbiota because it 
is easy to collect. Nevertheless we have to distinguish between mucosal microflora 
and faecal microflora but up until now the exact differences are not clear (Eckburg, 
Bik et al. 2005).  
About 40-80% of microbiota which are detected under the microscope are impossible 
to culture at the moment; and even if they are cultivable, experience is necessary 
and the individual interpretation indeed differs (Tannock 2001; Guarner and 
Malagelada 2003; Penders, Stobberingh et al. 2007). 
New techniques arose with whom, uncultivable species are detectable. The samples 
can be kept frozen for later analysis and furthermore anaerob handling and expertise 
is not necessary (Furrie 2006; Penders, Stobberingh et al. 2007). 
Bacterial communities are analyzed with the aid of the small ribosomal sub-unit RNA 
because it contains hypervariable regions which contain the signature of 
phylogenetic groups and sometimes even species (Tannock 2002; Penders, 
Stobberingh et al. 2007). The sequencing of the 16S rRNA gene from clone libraries 
pointed that uncultivated species and novel microorganisms make up the largest 
amount of the gut microbiota (DiBaise, Zhang et al. 2008). 
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For studying gut microbiota the Fluorescent in situ hybridisation (FISH) and the 
Polymerase chain reaction (PCR) used together with a denaturing or temperature-
gradient-gel-electrophoresis (DGGE/TGGE) are useful for studying the gut 
microbiota. The real time PCR is another molecular technique (Zoetendal, Collier et 
al. 2004; Penders, Stobberingh et al. 2007). 
FISH is a technique, which is adequate for assessment of the spartial distribution of 
the bacteria in the intestine. Fluorescent oligonucleotide probes detect 16S ribosomal 
RNA sequences of intact bacterial cells (Tannock 1999). This technique is insensitive 
and the detection limit are 106 bacterial cells per gram (Penders, Stobberingh et al. 
2007). PCR-TGGE/-DGGE is a further molecular method which is insensitive as well 
and unsuitable for analyses of large sample numbers. In addition, a quantitative 
assessment is not possible with this method because it generates a bacterial 
fingerprint of the composition in the faeces (Penders, Stobberingh et al. 2007). The 
bacteria DNA is extracted from faeces and the PCR amplifies the fragments of the 
16s rRNA gene and afterwards the TGGE/DGGE separates the 16s molecular 
species. A polyacrylamide gel is needed in which the double stranded 16s fragments 
migrate until they are fully denaturized (Tannock 1999; Tannock 2002; Penders, 
Stobberingh et al. 2007). The quantitative real-time PCR is suitable for assessment 
of quantitative amounts of bacteria in the intestine. The amount of PCR products of 
DNA are amplified due to fluorescent oligonucleotide probes and the quantitative 
real-time PCR can determine the abundance of PCR products. The amplicon 
concentration is demonstrated by the fluorescent intensity which is emitted during the 
amplification. During amplification it cycles changes in amplicon concentration 
emerge and thereby an estimation of DNA/RNA target is possible (Mackay 2004; 
Zhang and Fang 2006; Penders, Stobberingh et al. 2007). 
Ascending necessity for identification and quantification of small groups which gain in 
importance makes a more frequent sequencing function inevitable. These increased 
sequence requirements are covered by 454 sequencing (Petrosino, Highlander et al. 
2009). 
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1.2. MICROBIOTA AND DISEASES 
Several studies have demonstrated that not a specific pathogen but rather a broad 
spectrum of bacteria influences the induction of intestinal inflammation (Andoh and 
Fujiyama 2006). A series of studies indicate that microbiota influence the 
development of obesity, inflammatory bowel diseases, atopic diseases, diarrhea and 
constipation (Mai and Draganov 2009) which are precisely discussed in this work, but 
further exist.  
 
1.2.1. Inflammatory Bowel Disease 
It is a general term for a group of chronic inflammatory disorders including the main 
forms Ulcerative colitis (UC) and Morbus Crohn (CD). The precise aetiology is not 
established until now (Reiff and Kelly 2009). Two hypotheses exist, the first suggests 
that a dysregulation of the mucosal immune system is the primary cause which leads 
to immunologic responses to the normal microflora. The second declares that an 
alteration in the bacteria in the gut or a decreased epithelial barrier function is the 
cause for an excessive mucosal immune response against microbial antigens  
(Strober, Fuss et al. 2007). However it is certain that an abnormal response of the 
immune system is the cause for this disease. Determined is the abnormality by 
genetic, as well as environmental factors. The hygiene hypothesis, which suggests 
that a restricted exposure of microbes increase the susceptibility for autoimmune 
diseases, plays an important role indeed. The Toll-like-receptors on colonocytes 
respond abnormally to the commensal bacteria which lead to an activation of the 
immune system and of the T lymphocytes (Roy, Kien et al. 2006). 
 
1.2.1.1. Etiology  
It is certain that the pathologic process is almost certainly driven by an aberrant local 
immune response. There is the assumption that more than one factor triggers 
inflammatory bowel diseases (Baumgart and Sandborn 2007). 
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Genetic-factors 
Some studies have shown and the fact that the illness occurs cumulative in first 
degree-relatives, it is therefore obvious that it is driven genetically (Baumgart and 
Sandborn 2007). 
Immunological-factors:  
Whenever it is possible for antigen constituents of the intestinal flora to infiltrate the 
mucosa barrier and there inducing a defence reaction arising by reason of already 
existing alterations of the immune system, it can lead to inflammatory reactions. 
Many studies confirm that there is an interaction between intestinal flora and the 
immune system (Baumgart and Sandborn 2007). 
With inflammatory bowel disease, the largest immunological compartment is affected, 
the intestinal mucosa associated immune-system. It exist a disturbance of the 
intestinal immune-regulation. An imbalance between pro- and contra- inflamed 
cytokines leads to the inflammation (Stange 2004). Innate as well as adaptive 
immune systems play an important role in the pathogenesis of IBD. 
The innate mucosal immune system: 
In healthy individuals, the intestinal epithelium together with an overlying mucin layer 
acts as a strict barrier between luminal microenvironment and the GI mucosa. The 
transit across the epithelial barrier is regulated through tight junctions. For tolerance 
promotion antigens, which are present in the lumen, are taken up from M cells and 
dendritic cells and presented to lymphocytes in the Peyers patches. The pattern 
recognition receptors like Toll like receptors (TLR) and Nucleotide binding 
oligomerization domain (NOD) receptors are also part of the innate immune system. 
The pattern recognition receptors adhere to “pathogen-associated molecular 
patterns” (PAMPs) which are present on noneukaryotic organisms. Due to this 
adherence, NF-κB becomes activated inducing the expression of inflammatory 
mediators. Furthermore invading pathogens lead to a chemotatic accumulation of 
neutrophils within the GI mucosa. The neutrophils produce reactive oxygen 
controvert the invading pathogens (Arseneau, Tamagawa et al. 2007). 
Defect of innate immune system in IBD: 
Ulcerative colitis patients have higher amounts of neutrophils leading to an increased 
generation of reactive oxygen. Patients with Crohn’s disease carry mutations of 
pattern recognition receptors leading to an increase in intestinal permeability and an 
elevated invasion of pathogens.  Polymorphisms in NOD2, MDR-1, OCTN, DLG5 
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and TLRs genes are associated with Crohn’s pathogenesis. Polymorphisms in TLR4, 
TLR5 and TLR9 genes are associated with the CD pathogenesis.  Consequently the 
TLR family is directly involved in the pathogenesis of Crohn’s disease. The defects of 
the receptors lead on the one hand, to an impaired ability to recognize pathogen 
bacteria and induce appropriate immune responses; and furthermore on the other 
hand the tolerance towards the gut’s commensal flora is disturbed. In addition, the 
intestinal epithelial barrier function is decreased in patients with Ulcerative Colitis and 
Morbus Crohn. An altered expression of tight junctional proteins controlling the 
epithelial paracellular permeability is also a cause for increased permeability. The 
“leaky gut” is disastrous for the immune cells in the intestinal mucosa. If this defect is 
cause for the pathogenesis of this illness, probiotics might be a therapeutic target 
because through this invasion of bacteria, the normally benign commensal strains 
are overwhelmed and inflammation can spread (Arseneau, Tamagawa et al. 2007). 
Adaptive Immune system: 
Specific antigen recognition and cell mediated immunity belong to the adaptive 
immune response. After Antigen presenting cells phagocytise the invading pathogens 
they present them to naïve CD4 T cells.  Subsequently a differentiation of the T cells 
to regulators T-cells or effector T cells proceeds. In dependence of the phenotype of 
the Effector T helper cell (TH1, TH2, Th17), the expression of unique cytokine profile 
takes place. After the pathogen is removed, the T regulatory cells express regulatory 
cytokines like IL-10 and TGFβ and thereby suppress inflammation. The consequence 
is a restoration of the gut homeostasis (Arseneau, Tamagawa et al. 2007). 
Defect in Adaptive Immune response in IBD: 
Polarizing cytokines initiate an enormous increase in accumulation of T-cells in the 
intestinal mucosa leading to inflammation development in IBD patients.  Down-
regulation of apoptosis prevents the body’s ability to clear the pathogenic T-cells and 
further aggravates the conditions in the intestinal mucosa. Originally the hypothesis 
that Crohn’s disease is Th1 mediated and Ulcerative Colitis is Th2 mediated. In 
recent years several findings have led to the assumption that a strict Th1/Th2 
paradigm is no longer adequate for defining the complexity of immune responses in 
IBD pathogenesis. Furthermore the newly detected phenotype of effector CD4 helper 
cells Th17 plays an important role in patients with IBD.  Th17 expresses IL-17 and IL-
22, especially occurring in patients with Crohn’s disease promoting inflammation 
development. These findings lead to the indication that Th1, Th2 and Th17 play an 
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important role in the innate immune response in IBD pathogenesis (Arseneau, 
Tamagawa et al. 2007). 
Environmental factors: 
Environmental factors play an important part because in epidemiologic data it is 
evident that the incidence of IBD correlates with the industrial development. NSAR 
(non-steroidal anti-inflammatory drugs (Aspirin)) can lead to an illness attack 
because of their impact on the mucosal barrier. Smoking reduces the risk to contract 
Ulcerative Colitis but it increases the risk for Morbus Crohn (Baumgart and Sandborn 
2007). 
 
For quite some time, inflammatory bowel disease was seen as a psychosomatic 
disease. More recently the supposition exists that it is primarily an organic disease, 
which can have, as all chronic diseases, psychosomatic concomitants. The present 
model for further discussion supposes that environmental factors in individuals with a 
genetic burden can lead to a lapse of the immune system (Baumgart and Sandborn 
2007). 
 
Ulcerative Colitis and Morbus Crohn both belong to inflammatory bowel disease. 
Ulcerative colitis and Morbus Crohn differ mainly in the location and the nature of the 
inflammatory changes. While Morbus Crohn can affect the entire gastrointestinal tract 
from mouth to anus, Ulcerative Colitis is restricted to the colon and the rectum. 
Furthermore Crohn´s disease affects the entire bowel wall, whereas Ulcerative Colitis 
is restricted to the mucosa. In the first diagnoses, 10% of cases can not be 
determined as Morbus Crohn or Ulcerative Colitis (Baumgart and Sandborn 2007). 
 
1.2.1.2. Questionnaire 
As a result of the ascent in patients suffering from IBD, initiatives have arisen to help 
those identified to suffer from this disease. This following link, http://www.ced-
check.at/cedcheck.shtml offers the possibility to check if one has or might have 
contracted inflammatory bowel disease. To find out, one must answer the questions 
with either yes or no, and if one answers yes to just one question, they are 
susceptible for IBD and should seek medical attention. 
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IBDIS-CED Check 
Wenn auch nur eine der Fragen 1-6 mit einem JA beantwortet werden muss, gibt es 
einen Hinweis auf eine Chronisch Entzündliche Darmerkrankung. Bitte wenden sie 
sich in diesem Fall unverzüglich an Ihren Hausarzt! 
 
1) Besteht/bestand länger als 4 Wochen Durchfall (= mehr als 3 flüssige Stühle pro Tag) 
oder wiederholte Episoden von Durchfällen? Angabe nötig ? 
 
 
2) Besteht/bestand länger als 4 Wochen Bauchschmerzen oder wiederholte Episoden 
von Bauchschmerzen? Angabe nötig ? 
 
 
3) Besteht/bestand regelmäßig oder wiederholt über mehr als 4 Wochen Blut im Stuhl? 
Angabe nötig ? 
 
 
4) Bestehen/bestanden nächtliche Bauchbeschwerden wie Bauchschmerz oder 
Durchfall? Angabe nötig ? 
 
 
5) Besteht/bestand regelmäßig oder wiederholt über mehr als 4 Wochen schmerzhafter 
Stuhldrang? Angabe nötig ? 
 
 
6) Bestehen/bestanden Fisteln oder Abszesse im Analbereich? Angabe nötig ? 
 
 
 
nein ja 
nein ja 
nein ja 
nein ja 
nein ja 
nein ja 
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7) Besteht/bestand allgemeines Krankheitsgefühl, Schwäche oder Gewichtsverlust? 
Angabe nötig ? 
 
 
8) Bestehen/bestanden Beschwerden außerhalb des Magen-Darm-Traktes wie 
Gelenksschmerzen, Augenentzündungen oder spezifische Hautveränderungen (z.B. 
„Erythema nodosum“: Kennzeichnend dafür sind z.B. mehrere, unscharf begrenzte Flecken 
bzw. Knötchen unter der Haut, die leicht erhaben und sehr druckempfindlich sind). Angabe 
nötig ? 
 
 
9) Existiert in der Familie ein Hinweis auf Morbus Crohn oder Colitis ulcerosa? Angabe 
nötig ? 
 
 
10) Können andere Ursachen einer Durchfalls-Erkrankung ausgeschlossen werden? (z.B. 
Fernreisen, Infektionen, Nahrungsmittelunverträglichkeiten, Medikamenteneinnahme wie 
NSAR (Antirheumatika) oder Antibiotika, sexuelle Praktiken). Angabe nötig ? 
 
 
 
 
http://www.ced-check.at/cedcheck.shtml 
 
1.2.1.3. General Nutritional Requirements 
Genetic susceptibility, environmental factors and aberrant immune responses seem 
to play an important role in the development of IBD (Shanahan 2001). Environmental 
factors are the local micro environment as well as the nutritional environment 
(Bernstein and Shanahan 2008). New lifestyles can be a reason why IBD has 
increased in the past years. The diet is an important component which should be 
considered in treatment of the illness. The consumption of cow’s milk by children, 
food with high amounts of refined sugar and fat and the decline in consuming fiber, 
fruits and vegetables could be detrimental (Lucendo and De Rezende 2009). 
nein ja 
nein ja 
nein ja 
nein ja 
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Breastfeeding is known to have a protective factor. Children who were breastfed over 
a short period of time had an increased risk for IBD, compared with children who 
were fed for a longer time. Breastfeeding seems to be protective because it provides 
against gastrointestinal infections, enhances the development of the gastrointestinal 
mucosa and improves the immunological capacity in children. Breast feeding enables 
a delayed contact with cow’s milk, infectious agents and other allergens. 
Mycobacterium avium paratuberculosis is an infectious agent, originating from 
infected cows and is therefore transmitted via cow’s milk. This bacterium is supposed 
to play a role in the development of CD. Nevertheless the epidemiological support is 
too little (Lucendo and De Rezende 2009). 
Although it’s not really proven, several investigators have suggested the consumption 
of low-refined carbohydrates for CD patients. The fat type might also play a role in 
IBD. The vast increase of fast food consumption in recent years may be associated 
with the development of UC. Increased consumption of monounsaturated as well as 
polyunsaturated fatty acids increased the risk for UC. While n-3 polyunsaturated fatty 
acids (PUFAs) might have a protective factor due to their anti-inflammatory 
properties, n-6 PUFAs are supposed to be detrimental due to their pro-inflammatory 
properties (Lucendo and De Rezende 2009). 
 
Patients who suffer from IBD might have an increased necessity for proteins and 
calories but it’s not entirely clear because the question is not clarified whether these 
deficiencies are cause or consequence of the disease. In patients with CD, calorie-
protein malnutrition is common, whereas in UC protein malnutrition is very often. 
Inflammatory mediators like TNF-α, Interleukin-1 and Interleukin-6 are responsible for 
an increased catabolism and lead to anorexia. Iron, folic acid, zinc, selenium and 
vitamin B12 are often detrimentally reduced. Furthermore IBD patients have an 
increased risk for osteoporosis and osteopenie due to a vast depletion of bone mass. 
Alongside other factors like genetic factors, female gender, smoking, the consistent 
use of corticosteroids, age and type of IBD and hormonal factors, inflammatory 
cytokines like TNF-α stand in association with increased bone loss (Lucendo and De 
Rezende 2009). 
A deficit of folic acid increases risk for colitis associated carcinogenesis. Deficiency 
occurs due to sulphasalazine or methotrexate. Folic acids as well as Vitamin B12 are 
essential in the metabolic route of homocysteine-methionine. Zinc is important for 
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healing wounds and a protective factor for cell damage caused by free radicals. 
Selenium is an important component in gluthatione-peroxidase. Oxidative stress fuels 
inflammation, therefore antioxidants like vitamin A,C, E and Selenium are important 
components for inhibiting inflammation (Lucendo and De Rezende 2009). 
 
Nutrition is an important aspect for patients with IBD. First, IBD patients are a risk 
group for malnutrition, second, it’s the primary therapy in the active phase of the 
disease and furthermore important in maintaining remission, and third, nutrients are 
risk factors which are involved in the aetiology of IBD. 
Those who suffer from IBD are vulnerable for osteoporosis, malnutrition, 
micronutrient deficiency and growth and development in children could be negatively 
influenced. Thus nutritional care is very important (Hartman, Eliakim et al. 2009). 
20-40% of CD outpatients have a significant weight loss due to their illness (Van 
Patter, Bargen et al. 1954; Lanfranchi, Brignola et al. 1984). In UC patients it is not 
as critical but during the active phase of the disease a nutrient deficiency can 
develop in a short period of time (Rocha, Santana et al. 2009). 
Malnutrition is caused by a decreased food intake (due to intolerances), a 
malabsorption of nutrients, an increased intestinal loss, hypermetabolic state and the 
interaction between drugs and nutrients. Although analyses of IBD patients have 
shown that most patients in remission are in a good nutritional condition there are 
remarkable abnormalities in the body composition (Hartman, Eliakim et al. 2009). A 
decrease in muscle mass was observed in more than half of UC and CD patients, 
though they were not malnourished. In the active phase of CD parameter like BMI, 
arm muscle area and triceps as well as subscapular skin fold thickness values were 
remarkably decreased (Rocha, Santana et al. 2009). In addition, although the 
patients were in remission, CD patients had a significant decrease in plasma 
concentration as well as lower amounts of vitamins and minerals (Hartman, Eliakim 
et al. 2009). 
 
1.2.1.3.1. Nutrition 
Patients who suffer from IBD are recommended to consume a healthy well balanced 
diet. Approximately 2000 kcal per day should be taken up whereas 15% of nutritional 
energy should be composed of protein, 30% should be composed of fat and 55% 
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should be composed of carbohydrates.  Meat should be consumed only 2-3 times a 
week and fish 1-2 times a week. The consumption of Omega-3-fatty acids should be 
elevated and 5 portions of fruits and vegetables per day are recommended (Kluthe, 
Dittrich et al. 2004). 
 
Diet should be rich and varied including fruit, vegetables, meat, olive oil, and fish. 
During flares of the disease, the consumption of fibers might be restricted. 
Nevertheless there is no supporting data. Milk products are urgently necessary, due 
to their high calcium content. Just in those cases of lactose intolerance, one must 
substitute milk with fermented products such as yoghurt, cheese, calcium enriched 
soya products, etc. (Lucendo and De Rezende 2009). The consumption of citrus 
fruits, fruit juices and vegetables could have a preventive factor for IBD. Until now it’s 
not clear whether the protective role comes from the fiber content in this edibles or if 
other micronutrients that might be the important components. Due to colonic 
fermentation of dietary fibers and other unabsorbable carbohydrate, short chain fatty 
acids like butyrate are generated. In UC patients, a deficiency of SCFA and a 
decreased oxidation rate was recognized (Lucendo and De Rezende 2009). 
 
Edibles which are responsible for initiating intolerances in more than 5% of patients 
should be excluded in the diet. Generally patients should avoid: 
• high fat diet especially fried and roasted food   
• high fat or smoked meat, sausages or fish 
• hard boiled eggs, mayonnaise and high fat scrambled eggs 
• high fat dairy products 
• high fat soups and sauces 
• fresh bread, fat bakery products and rough wholemeal products 
• preparations of fried potatoes 
• vegetables which are flatulent or indigestive for example cabbage, sauerkraut, 
field garlic, onion, paprika, mushrooms, olives, cucumber, radish,  dried 
legumes 
• vegetables which are prepared with an high fat amount 
• immature fruits, stone fruits, nuts, almonds, pistachio, avocados 
• fat sweets 
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• alcohol in every form 
• carbonated beverages 
• iced beverages 
• high amounts of hot spicery, onion and garlic powder 
(Kluthe, Dittrich et al. 2004) 
 
1.2.1.3.2. Parenteral Nutrition 
Parenteral nutrition is not as common since investigators have found that enteral 
nutrition is as effective and causes lower costs and has fewer significant side effects. 
Exceptions are cases with severe malnutrition or support before or after a surgery in 
CD and UC (Hartman, Eliakim et al. 2009). 
 
1.2.1.3.3. Enteral Nutrition 
Enteral nutrition (EN) is not proven to be used as primary therapy in UC. 
Nevertheless supplementary enteral nutrition might be effective in patients with CD 
for maintaining remission. Several studies showed that enteral nutrition induced 
clinical remission, enhanced nutritional status, enhanced body composition, boosted 
mucosal healing, lowered the production of pro-inflammatory cytokine levels, and a 
decline of serum inflammatory markers was also observable in CD patients 
(Hartman, Eliakim et al. 2009). 
Enteral nutrition has not shown to have advantages, in comparison to steroids, in the 
vast majority of CD patients. If patients have a steroid intolerance, refuse steroids or 
if patients have inflammatory stenosis of the small intestine, enteral nutrition could be 
an alternative for steroids. Patients who are undernourished might receive EN as well 
as steroids. However in children with active CD enteral nutrition plays a greater role. 
EN is as efficient as steroids in this group. A replacement of steroids with EN might 
be an opportunity to avoid the negative side effects of steroid’s retarded growth and 
development of children (Smith 2008). Enteral nutrition should be recommended as 
primary treatment for all patients who suffer from CD and for patients with serious 
cases from UC. It’s also possible to add it to medical treatment as a second 
treatment to achieve or maintain remission. Enteral feeding is advantageous in 
patients with CD if the small intestine is affected, whereas in patients with UC an 
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urgent necessity is not established. Enteral nutrition might modulate the immune 
system in the mucosa, regulating imbalances in the microbiota composition which are 
responsible for the inflammation (Lucendo and De Rezende 2009). 
 
Mechanisms of Enteral Nutrition: 
(1) Improved nutritional status 
(2) Pro-inflammatory cytokines are down-regulated 
(3) Anti-inflammatory actions 
(4) Promotion of epithelial healing 
(5) A decrease in gut permeability 
(6) Decreased antigenic load to the gut 
(7) Modification of the gut flora 
(Hartman, Eliakim et al. 2009) 
 
Variants of Enteral Nutrition 
Elemental as well as polymeric formulas are variants for enteral nutrition. Elemental 
formula and polymeric formula are efficacious in the same way (Hartman, Eliakim et 
al. 2009). Polymeric diet contains nitrogen in the form of whole protein. 
Carbohydrates are contained in the form of hydrolysates of starch, and medium chain 
fatty acids provide the fat contingent. Fibers are also contained, although their 
effectiveness has not been proven until now. Elemental diet is composed of simple 
nutrient forms like amino acids, simple carbohydrates, fats, vitamins and minerals 
and are therefore easier in digestion (Smith 2008). Nonetheless the polymeric 
formula seems to have some advantages (Hartman, Eliakim et al. 2009). In a trial 
with children who suffered from CD polymeric formula was more adequately  for 
gaining weight which is desirable for paediatric CD (Ludvigsson, Krantz et al. 2004). 
Polymeric formula is more palatable than elemental enteral nutrition and therefore 
more compliant. Furthermore it is cheaper and there seem to be no differences 
between polymeric and elemental diet in their efficiency (Smith 2008). 
In enteral nutrition, the fat content is supposed to play an underlying role. Enrichment 
with bioactive peptides like glutamine, growth factors, butyrate omega-3 fatty acids 
and anitoxidants might have an anabolic or anti-inflammatory effect. However until 
now the advantages of such additions in elemental diet is not proven (Hartman, 
Eliakim et al. 2009). 
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Patients with CD have an increased gut permeability which allows increased uptake 
of antigens which might be a factor for enhanced inflammation. Elemental diet 
decreases gut permeability, thus it might have a positive effect. Components of the 
elemental diet are primary absorbed in proximal small bowel. The decreased 
digestion and peristaltic might play a role indeed (Smith 2008). 
 
Exclusively Enteral Nutrition  
Steroids and exclusively enteral nutrition (EEN) were compared in children with CD. 
EEN was found to be as effective as corticosteroids in inducing remission. EEN has 
in comparison to steroids the advantage that they have no side effects. Therefore 
they might be a preferred choice for first-line therapy in children with active CD. 
Johnson et al. declared that partial EN (PEN) in comparison to EEN was not as 
effective in children with CD for inducing remission (Hartman, Eliakim et al. 2009). 
 
1.2.1.3.4. Probiotics 
Due to the fact that the inflammation occurs in parts of the intestine in which the 
highest bacterial load occurs, probiotics might be appropriate for disease 
improvement. Furthermore it has been proven that an interruption of the faecal 
stream alleviates the disease symptoms. An increased mucosal permeability which 
leads to direct contact to bacteria is a further reason. Genetic susceptible individuals 
have a loss of immunological tolerance to commensal bacteria and this, in addition 
points out that treatment with probiotics might be helpful (Bergonzelli, Blum et al. 
2005). 
 
 
1.2.1.4. Ulcerative Colitis 
Ulcerative colitis is a type of inflammatory bowel disease. The initiation of the disease 
is due to an unbalanced immune response to luminal antigens (Mitsuyama, 
Matsumoto et al. 2008). 
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1.2.1.4.1. Clinical Picture 
Ulcerative Colitis is a chronic inflammation which is limited to the mucosa of the colon 
and the rectum. The initiation takes place in the rectum and in approximately half of 
the patients, it spreads in the proximal direction. The inflammation is limited to the 
mucosa and mainly the crypt epithelium is affected through abscesses. The mucosa 
is reddened and inflamed leading to bloody diarrhea and abdominal pain. Ulcerative 
colitis is a continuous inflammation which means that the inflamed alterations spread 
from the rectum in the oral direction and do not overleap healthy mucosa parts 
(Baumgart and Sandborn 2007). 
The extension of the inflammation determines if it’s a proctitis where just the rectum 
is affected, a proctosigmoiditis where the rectosigmoid colon is affected or a left-
sided colitis where the descending colon is involved. A pancolitis means that the 
entire colon is affected. In such a case, enemas can not reach the entire damaged 
area (Renz-Polster and Krautzig 2008). 
Symptoms: 
The main symptom is bloody and mucous diarrhea. Furthermore abdominal pain and 
general symptoms like weight loss, nausea, absence of appetite and fever occurs. In 
the acute attack, 10-20 bloody and mucous bowel movements are common; 
tenesmus is also possible. The loss of blood and the inflammation can lead to 
anaemia and hypoproteinaemia. Extraintestinal Symptoms can also occur, but are 
not as common as in Morbus Crohn (Renz-Polster and Krautzig 2008). 
The severity of the disease can differ and so in clinical practice they distinguish 
between mild, moderate, severe and fulminant activity. A mild activity is 
characterized by up to four bloody stools daily without toxicity, a moderate activity 
exists if there are four to six bloody stools daily with minimal toxicity, and a severe 
activity is characterized by more than six bloody stools daily accompanied by fever, 
tachycardia, anaemia and a raised erythrocyte sedimentation rate. Fulminant colitis is 
characterised by more than ten bloody stools daily accompanied by high fever, 
extensive bleeding, increased inflammation markers, and weight loss (Baumgart and 
Sandborn 2007). 
Course: 
An attack can last from 1 to 8 weeks. Between this time, patients have symptom free 
intervals which can last from months to years (Renz-Polster and Krautzig 2008). 
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1.2.1.4.2. Therapy 
Quintessentially fort this disease is the remission and relapse period. Therefore the 
prior treatment are immunosuppressive drugs and anti-inflammatory drugs (Herias, 
Koninkx et al. 2005). 
 
1.2.1.4.2.1. Medical Treatment 
5-Aminosalicylic acid (mesalazine) is the primary therapy for patients with mild or 
moderate activity. If this treatment is not effective a therapy with oral corticosteroids 
like prednisone or budesonide is necessary. Patients who require frequent steroid 
therapy should change to treatment with azathioprine or mercaptopurine. If the 
treatment with one of the two is not effective Infliximab is recommended for therapy. 
Infliximab is a chimeric monoclonal antibody to TNF-α. Patients with severe or 
fulminant Ulcerative colitis receive only medical therapy as long as it’s not toxic. The 
first line therapy is an Intravenous Corticosteroids treatment. If there is no response 
after 5 days, other medical alternatives are Infliximab, Ciclosporin and Tacrolismus. 
To maintain remission, oral mesalazine therapy is common. If this is not effective 
azathioprine or mercaptopurine and infliximab treatment is established (Baumgart 
and Sandborn 2007). 
 
1.2.1.4.2.2. Surgical Treatment 
Perforation, refractory rectal bleeding and toxic megacolon are urgent causes for 
surgery, especially when they are not responsive to medical treatment. Dysplasia, 
cancer, intolerance to long-term immuosuppression or ineffectiveness to medical 
treatment might also be a cause for a surgery. The most common technique is the 
total proctocolectomy. Complications after the surgery are pouchitis, high stool 
frequency, faecal inconsistence and reduced fertility. There is also the risk for a 
necessity of reoperation (Baumgart and Sandborn 2007). 
 
1.2.1.4.3. Composition and Differences to Normal Microbiota 
Bacteria are supposed to be involved in the development of colitis because studies 
with germ-free mice have shown that these rodents were not able to develop 
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disease. The number of Lactobacilli was reduced in the faeces in patients with active 
UC in comparison to those who were in remission. Nevertheless the total 
concentration of bacteria was increased, but on the contrary the biodiversity reduced. 
Enterobacteria were increased in particular E.coli B2 + D groups. The UC patients 
had higher amount of sulphate reducing-bacteria. These bacteria produce hydrogen 
sulphide whereby they inhibit butyrate oxidation which results in colonic lesions. The 
numbers of Bifidobacteria were lower in UC patients than in controls. The results of 
Bacteroidetes are controversial. As well as an increased amount, as an decreased 
amount was detected in several studies (Sokol, Lay et al. 2008). The antibody 
production against obligate anaerobes as well as the mucosal IgG against normal 
colonic microbiota is elevated in patients with Ulcerative colitis. There is the 
assumption that bacteria are involved in initiation as well as in maintenance of the 
disease. Fusobacteria, shigella, salmonella and yersinia have an association with 
ulcerative colitis. Facultative anaerobes are increased in the faeces of IBD patients. 
In a study with the healthy individuals and nine UC patients, investigators analyzed 
the bacteria of the mucosa in the rectal epithelium. They noticed that healthy 
individuals had a 30-fold higher level of Bifidobacteria than UC patients. 
Bifidobacterium angulatum and Bifidobacterium bifidum occurred in both groups, but 
in UC patients Bifidobacterium angulatum it was most prevalent, whereas in healthy 
individuals Bifidobacterium adolescentis dominated (Macfarlane, Furrie et al. 2005). 
In other studies a decreased Bifidobacterium content occurred as well but also in 
association with an increase of Bacteroides (Pathmakanthan, Thornley et al. 1999; 
Macfarlane, Furrie et al. 2005). Matsuda et al. has already concluded that 
Peptostreptococci only occurs on the mucosal surface of UC patients but not on 
healthy individuals (Matsuda, Fujiyama et al. 2000; Macfarlane, Furrie et al. 2005). 
Macfarlane et al. agrees with this result. Peptostreptococci and E.faecalis occurred in 
UC patients but not in healthy individuals.  An analysis of the rectal epithelium with 
the microscope showed that the majority of the bacteria were growing in 
microcolonies. This might lead to higher concentrations of produced antigens or 
toxins (Macfarlane, Furrie et al. 2005). 
In another trial, investigators compared the faeces of Ulcerative Colitis patients with 
that of healthy individuals. They diagnosed that patients with Ulcerative Colitis had 
lower counts of Firmicutes, especially the species Faecalibacterium prausnitzii was 
underrepresented in patients with active inflammatory bowel disease. Furthermore 
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patients with active colitis had lower counts of Bifidobacterium in comparison to 
healthy individuals. The conclusion of this study was that all patients with active 
colitis had a decrease of the Firmicutes/Bacteroidetes ratio.  Yet investigators also 
pointed out that until now it is not clear whether the changed composition of bacteria 
in colitis patients is responsible for the inflammation, or if the change of bacteria is 
the consequence of the inflammation. Anyhow, the results allude, that the decrease 
of Firmicutes especially Faecalibacterium prausnitzii is involved in the development 
of inflammatory bowel disease (Sokol, Seksik et al. 2009). 
Until now it is not clear if the changes of the gastrointestinal microbiota are primary or 
a secondary phenomenon. It could be possible that an alteration in motility and diet in 
patients with IBD leads to alterations of the colonic microenvironment and is reflected 
to the microbiota, or a change in microbiota is the primary phenomenon (DiBaise, 
Zhang et al. 2008). 
Dominant bacteria appear to be relatively stable in each individual, no matter if the 
tissue is ulcerated or non-ulcerated. In contrast, the number of Lactobacilli and 
Clostridium leptum varied in the same individual in dependence if the tissue was 
ulcerated or not. The number of Lactobacilli in the mucosa is significantly decreased 
in patients with IBD. Lactobacilli have beneficial functions for the host and many 
studies have already shown that they can reduce the severity and maintain remission 
in this disease (Zhang, Liu et al. 2007). 
In a study from Ott et al., investigators conducted biopsies of CD patients, UC 
patients and healthy individuals. In patients with Ulcerative Colitis the bacterial 
diversity was reduced by 30% compared with healthy controls. Especially a decline of 
anaerobic bacteria like Bacteroides species, Eubacterium species and Lactobacillus 
species were the result of the diseases (Ott, Musfeldt et al. 2004). 
Characteristic features of this disease are an inflamed mucosa and a disturbed 
mucosal barrier. In the inflamed large intestine of the mucosa, there are much more 
bacteria than in healthy individuals. The inflammation of the mucosa leads to an 
invasion of microorganisms. In the large intestine of colitis patients are the apical 
surface; furthermore the mucosal epithelial cells colonised with microorganisms 
which is not prevalent in healthy individuals. The amount of inflammation-markers 
correlate negatively with the amount of bacteria in the mucosa (Schulze, Sonnenborn 
et al. 2008). 
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Author UC patients Healthy Individuals 
(Sokol, Lay et al. 2008) Bacterial load ↑ 
Biodiversity ↓ 
Lactobacilli ↓ 
Enterobacteria ↑ 
Sulphate reducing bacteria ↑ 
 
(Macfarlane, Furrie et al. 
2005) 
Bifidobacterium angulatum 
predominant 
Peptostreptococci & E. faecalis 
only in UC patients 
Bifidobacteria 30 fold ↑ 
Bifidobacterium adolescentis 
predominant 
No Peptostreptococci & E. 
faecalis 
(Pathmakanthan, 
Thornley et al. 1999) 
Bifidobacteria ↓ 
Bacteroides ↑ 
 
(Matsuda, Fujiyama et al. 
2000) 
Peptostreptococci only in UC 
patients 
No Peptostreptococci 
(Sokol, Seksik et al. 
2009) 
Firmicutes:Bacteroides ratio ↓ 
Faecalibacterium prausnitzii ↓ 
Bifidobacteria ↓ 
 
(Zhang, Liu et al. 2007) Lactobacilli ↓  
(Ott, Musfeldt et al. 2004) Bacterial diversity ↓ 
Bacteroides ↓ 
Eubacterium species ↓ 
Lactobacillus species ↓ 
 
 
Table 1. Summarized results from studies investigating the differences of microbiota in UC 
patients. 
 
 
1.2.1.4.4. Probiotics and Counselling 
Patients in remission 
Studies showed that an increased consumption of meat is detrimental for colitis 
patients. Therefore patients should reduce their meat consumption to once a week. 
Hydrogen sulphides are increased in the gut of colitis patients in comparison to 
healthy individuals. Therefore “red” meat, cheese, milk, fish, nuts, eggs and alcohol 
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should be reduced. These are precisely suppliers for hydrogen sulphide. Hydrogen 
sulphide acts against the positive functions of butyrate. Prebiotics have shown 
positive effects in the gut of colitis patients because patients have low amounts of 
butyrate in the gut in comparison to healthy individuals. Butyrate has anti-
inflammatory effects and enhances the barrier function in the gut (Schiener, Reiterer 
et al. 2008). 
Active phase 
Generally speaking there is agreement that parenteral nutrition is only essential in 
cases of very aggressive forms of colitis.  Enteral nutrition is recommended for 
patients who are malnourished. Apart form that it is recommended that patients 
should consume a low-fiber diet during the active phase (Schiener, Reiterer et al. 
2008). 
 
Probiotics 
The pathogenesis of this disease might be associated with a disturbed microflora. 
“Aggressive” bacteria dominate in contrast to “protective” bacteria. With this account, 
possible disease alleviation might be the manipulation of the intestinal flora. The 
strategies appear promising, yet nevertheless further studies are needed to establish 
this administration (Andoh and Fujiyama 2006). Probiotics might be effective in 
treatment of UC patients, especially VSL#3, E.coli Nissle1917, Saccharomyces 
boulardii and Bifidobacterium-fermented milk have shown promising results 
(Mitsuyama, Matsumoto et al. 2008). 
VSL#3 
Administration of probiotics, especially VSL#3 can prevent or alleviate the symptoms 
of IBD. VSL#3 comprises of eight different lactic acid bacteria (Lactobacillus 
acidophilus, L.bulgaricus, L. casei, L. plantarum, Streptococcus thermophilus, 
Bifidobacterium breve, B. infantis, and B. longum). Unfortunately  probiotics are more 
adequate for maintaining remission than having an effect in severe active forms of 
IBD (Reiff and Kelly 2009). VSL#3 was effective for maintaining remission in UC 
patients. From 20 patients, 15 (75%) remained in remission during a 12 month 
treatment (Venturi, Gionchetti et al. 1999). Patients who were administered with 
VSL#3 in uncontrolled pilot studies maintained in remission over 12 months (Andoh 
and Fujiyama 2006). In a trial with UC patients, patients who were allergic or 
intolerant to sulphasalazine and mesasalazine were treated with VSL#3 over 12 
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months. The impact of the faecal flora was assessed. Only after 20 days a significant 
increase of Lactobacilli, Bifidobacteria, and Streptococcus thermophilus occurred, 
which was held stable as long as the treatment lasted. After the treatment stopped, 
the composition of the faeces turned to basal levels within 15 days. 75% of the 
patients remained in remission during the trial (Gionchetti, Rizzello et al. 2006). An 
Italian study conducted a study with 90 patients with mild to moderate disease 
activity and treated them either with low-dose balsalazide and VSL#3, or medium 
dose balsalazide, or mesalazine. The trial lasted for 8 weeks and those patients who 
received the combination of balsalazide and VSL#3 gained remission in the shortest 
time of all of them, and furthermore the most form this group achieved remission 
(Tursi, Brandimarte et al. 2004). A further study showed that in 32 patients with active 
and severe UC, administration with VSL#3 induced remission in 56% only after 6 
weeks. 25% had a response due to this treatment, and 9% had no response (Bibiloni, 
Fedorak et al. 2005). 
Lactobacilli 
Probiotics might have a beneficial effect by maintaining remission. Lactobacilli 
reuterii, Lactobacillus plantarum and Lactococcus lactis have been shown effective in 
mice studies (Macfarlane, Furrie et al. 2005). Lactobacillus rhamnosus GG lowered 
relapse time but did not decrease relapse rate (Reiff and Kelly 2009). Further results 
appeared that after an open labelled trial with active and mild UC patients, who were 
treated with Lactobacillus casei Shirota (LcS) for 8 weeks, a significantly better 
clinical activity index score occurred after treatment in comparison to the control 
group. Administration with LcS was more effective than the conventional therapy 
alone (Mitsuyama, Matsumoto et al. 2008). In a randomized open-label study, LGG 
was investigated at 187 patients in remission state.  Investigators concluded that, 
LGG is equivalent with mesalamine and therefore adequate for therapy (Zocco, dal 
Verme et al. 2006). 
Bifidobacteria 
A trial with eighteen active colitis patients was conducted in which patients either 
received a symbiotic composed of B.longum and a prebiotic or a placebo for 4 
weeks. In response to the symbiotic treatment, patients had significant reduction 
levels of inflammation markers (Macfarlane, Furrie et al. 2005). Alleviation of disease 
symptoms in UC patients was due to Bifidobacterium breve in a fermented milk 
product. In a Japanese study, 20 randomized patients received either the probiotic 
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combined with medical therapy or a placebo with medical therapy. Steroids were 
excluded during this trial. Results showed that the Bifidobacteria treatment was much 
more successful than the placebo administration (Kato, Mizuno et al. 2004).  In 
another trial, patients who were in remission received for 2 months sulfasalazine and 
glucocorticoid either followed by administration with Bifidobacteria or followed by 
administration with placebo.  During this time, only 20% of the probiotic group had a 
relapse whereas 93.3% of the placebo group relapsed. The inflammatory activity was 
further marked by a reduction in the Bifidobacteria group (Cui, Chen et al. 2004). 
E.coli 
In maintaining remission, E. coli Nissle 1917 is as effective as mesalazine 
(Gionchetti, Rizzello et al. 2006). Treatment with E.coli strain Nissle 1917 showed to 
be as effective as Mesalazine in maintaining remission in 120 UC patients (Kruis, 
Schutz et al. 1997). Because the first study population was too small, Kruis et al. 
conducted another study with 327 UC patients who for one year received either E.coli 
Nissle or mesalamine. One third of the patients discontinued, however the results 
showed that the remaining 222 patients that had E.coli Nissle administration had the 
same effect as mesalazine (Kruis, Fric et al. 2004). Rembacken confirmed these 
results due with the aid of 116 UC patients who received either mesalazine or a non-
pathogenic E.coli strain (Rembacken, Snelling et al. 1999).  
Saccharomyces boulardii 
Is able to induce remission in 71% of patients which are affected by mild to moderate 
disease course (Gionchetti, Rizzello et al. 2006). In a pilot study the effect of S. 
boulardii was investigated in patients with active UC. Patients who were intolerant to 
steroids received S. boulardii for 4 weeks and 17 of 24 patients thereby achieved 
clinical and endoscopic remission (Guslandi, Giollo et al. 2003).  
 
Prebiotics 
The effects of SCFA in Ulcerative colitis are inconsistent. 
Patients with ulcerative colitis have a lack of luminal short chain fatty acids because 
the uptake as well as the oxidation by colonocytes is blocked. Reduced Coenzyme A 
is responsible for the inhibited oxidation. Coenzyme A is reduced due to sulphur-
containing compounds which are produced by the colonic microbiota. An extensive 
administration with SCFA could counteract against the lowered uptake and the 
reduced oxidation. In a study with Ulcerative colitis active and quiescent patients, 
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Roediger et al. found that the butyrate oxidation in these patients were lower than in 
controls (Roediger 1980; Wong, de Souza et al. 2006). In another experiment Harig 
et al. conducted a treatment with a SCFA solution for 2 to 6 weeks. This led to an 
improvement in endoscopic appearance, and patients with rectosigmoid colitis, with a 
nutrient deficiency, had a higher inflammation state (Harig, Soergel et al. 1989; 
Wong, de Souza et al. 2006). Yet in another study with the same SCFA solution, no 
endoscopic or histological changes appeared after 2 weeks (Guillemot, Colombel et 
al. 1991; Wong, de Souza et al. 2006). An explanation for these contradictory 
findings could be the amount of SCFA, the type of SCFA and the frequency and 
duration of administration (Wong, de Souza et al. 2006). 
An inadequate energy supply of butyrate for colonocytes might be a detrimental 
factor for colitis. Until now it has not been clear in which amount butyrate would be 
the optimal concentration for treatment (Pryde, Duncan et al. 2002). 
The capacity in colon cells to oxidise butyrate is lowered in patients with ulcerative 
colitis. Therefore the levels of butyrate in the faeces were higher in colitis patients 
than in controls. An induction of remission was possible through administration with 
SCFA enemas (McOrist, Abell et al. 2008). Fructooligosaccharides (FOS) are 
present in barley in high amounts.  Consumption of barley reduced the clinical activity 
index. Unfortunately both studies which conducted this trial had a small number of 
patients and only one with such results (Kanauchi, Mitsuyama et al. 2003). 
 
1.2.1.4.5. Modern Molecular Findings, Probiotics 
In IL-10 knockout mice, it was observed that the mice developed colitis when they 
were raised under conventional conditions rather than germ-free conditions. Due to 
the administration of VSL#3, suppression of the mucosal TNF-α and IFN-γ production 
occurred and a normalization of barrier function and physiological transport was the 
consequence. Several reports document that VSL#3 has anti-inflammatory effects 
(Andoh and Fujiyama 2006). VSL#3 up regulates alkaline sphingomyelinase in the 
mucosa of the intestine and reduces inflammation (Reiff and Kelly 2009). 
IL-6 plays a key role in intestinal inflammation. The Lactobacillus casei strain Shirota 
(LcS) inhibited the Interleukin-6 production in lipopolysaccharide-stimulated 
peripheral blood mononuclear cells which were isolated from UC patients 
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(Mitsuyama, Matsumoto et al. 2008). Under normal concentration IL-6 is important for 
host defence (Matsumoto, Hara et al. 2005). 
In another experiment, investigators assessed the probiotic effect of LcS during the 
active phase and ten days after they induced dextran sodium sulphate (DSS) UC 
mice. DSS has been qualified for UC induction because it exhibits the characteristic 
symptoms of UC, it is capable of inducing acute as well as chronic UC and because 
the model is useful and reliable. The results demonstrated that LcS administration 
improved clinical parameters’ in comparison to controls. Nevertheless the LcS 
treatment could not inhibit an induction of UC. Further observations included, that 
due to the UC induction, equal in the LcS group or the control group a dramatic 
increase of Enterobacteriaceae occurred (Herias, Koninkx et al. 2005). In IL-6 gene 
knockout mice, the DSS induced Colitis was less severe. LcS derive a 
polysaccharide-peptidoglycan complex which down-regulates the IL-6 production in 
lamina propria mononuclear cells (LPMCs) in murine chronic colitis as well as ileitis in 
SAMP1/Yit mice (Matsumoto, Hara et al. 2005). An important relevance is the 
awareness that the PSPG complex of L.casei, neither the PSPG complex of 
L.rhamnosus has an impact on the inhibition of IL-6. Only the PSPG complex of LcS 
inhibts the IL-6 production in LPS-stimulated colonic lamina propria mononuclear 
cells. Furthermore only the LcS has the ability to inhibit phosphorylation of NF-κB in 
lipopolysaccharide stimulated RAW cells. Investigators found that PSPG is 
composed of two PSPG components: PSPG-I and PSPG-II. But only PSPG-I had the 
ability to inhibit  phosphorylation of NF-κB and IκB after the lipopolysaccharide 
stimulation in lamina propria mononuclear cells (Matsumoto, Hara et al. 2009). 
The inflammation markers seem to be reduced due to administration of Bifidobacteria 
(Cui, Chen et al. 2004; Macfarlane, Furrie et al. 2005). 
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1.2.1.5. Morbus Crohn 
1.2.1.5.1. Clinical Picture 
The disease develops in genetic susceptible individuals due to an aberrant immune 
response, which is directed against luminal antigens such as dietary factors or 
commensal bacteria (Andoh and Fujiyama 2006). The increased cytokine production 
leads to inflammation and further to tissue damage. CD4+ T lymphocytes play a 
major role because the mucosa of CD patients is heavily infiltrated in contrast to 
healthy individuals. Furthermore CD+4 T lymphocytes are resistant against 
apoptosis. In Crohn’s disease Th1 cells are predominant in the inflamed gut  (Fantini, 
Monteleone et al. 2007). 
Morbus Crohn is a discontinuous inflammation and in contrast to Ulcerative colitis it  
can potentially affect the entire gastrointestinal tract from mouth to anus (Baumgart 
and Sandborn 2007). The affection starts in the terminal ileum and extends in the 
course of time. In one third of individuals, simply the small intestine, especially the 
ileum (Iletitis), is affected; in one third the terminal small intestine and the large 
intestine is affected, and in one third of individuals only the colon is affected. In rare 
cases the proximal small intestine, the stomach or the mouth are also affected 
(Renz-Polster and Krautzig 2008). 
 
Because of the variable affection, clinical symptoms are much more diverse than in 
Ulcerative colitis. Like in Ulcerative colitis general symptoms and abdominal pain as 
well as diarrhea are predominant. Extra intestinal symptoms occur especially in 
young patients and in 50% of all Crohn-patients (Renz-Polster and Krautzig 2008). 
 
• Joint manifestations are common especially two different forms of arthritis: 
The nondeforming arthritis of the large joints and the central arthritis also 
called ankylosing spondylitis which can only occur in patients who are HLA-
B27-positive. 
• Skin manifestations: Frequently are Aphtous ulcers of the mouth and clubbed 
fingers. Erythema nodosum, and Pyoderma gangrenosum rarely occurs. 
• Liver and bile: Common is a fatty degeneration of the liverparenchym and 
Pericholangitis. Slcerosing Cholangitis with an increasing obstruction of the 
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biliary tract is more common in patients with Ulcerative Colitis than in Crohn-
patients and can lead to biliary cirrhosis.  
• Eyes Iritis, Episkleritis, Uveitis 
• Nephrolithiasis and gallstones 
(Renz-Polster and Krautzig 2008) 
 
In contrast to Ulcerative Colitis it is a discontinuous inflammation and the remission is 
not free of symptoms (Renz-Polster and Krautzig 2008). 
The cause for the disease is not clear until now. Genetic factors, a disturbance of the 
immune system as well as environmental factors might play a role in disease 
initiation. Intestinal or extraintestinal bacterial infections could initiate intestinal 
inflammation. Although some microorganisms are supposable, results of a single 
microorganism as the cause are controversial. In susceptible individuals the intestinal 
inflammation could be driven by pathogens by a disruption of the mucosal barrier. An 
increased uptake of luminal antigens is the consequence. Mimicry of self-antigens 
and modulation of NF-κB or other transcription factors lead to an activation of the 
mucosal immune system and are further causes for the inflammation. Enhanced 
mucosal permeability can be the primary (genetically predisposed) or the secondary 
effect of inflammation. The secondary effect might occur after contact with 
pathogenic bacteria or as a consequence of the inflammation. Increased mucosal 
permeability leads to a loss of tolerance to the non-pathogenic resident enteric 
bacteria. Lesions are especially in regions where the highest number of luminal 
bacteria exists. Alongside the importance of the enteric flora, which is responsible for 
the full expression of the disease, the manner in which the enteric immune system 
recognizes bacterial antigens is of particularly remarkable. Polymorphisms in the 
NOD2 gene leads to an ineffective immune response to bacterial components and a 
defect in the clearance of bacteria in the human epithelia (Sheil, Shanahan et al. 
2007). 
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1.2.1.5.2. Therapy 
The goal is to induce remission initially followed by the administration of maintenance 
medications to prevent a relapse of the disease. It is very important to find a way for 
an initial remission and keep the remission afterwards (Renz-Polster and Krautzig 
2008). 
 
It is not possible to cure patients who suffer from Morbus Crohn. In contrast, patients 
with Ulcerative Colitis have the possibility to carry out a colectomy which would cure 
the illness.  However, it is possible that after the operation a pouchitis would appear. 
The conservative therapy which is alike in both diseases is based on anti-
inflammatory, immunosuppressed and immunomodulating drugs. A dietary-therapy 
does sometimes help, especially in the acute attack (Renz-Polster and Krautzig 
2008). 
 
1.2.1.5.2.1. Medical Treatment 
The treatment is dependent on the disease location. Induction of remission in 
patients with mild ileocaceal or colonic disease is possible with sulfasalazine or 
mesalazine (ASA) but not effective for maintaining remission. If this treatment as first-
line therapy is not effective, prednisolone therapy is the second possibility. The 
treatment with infliximab is effective if none of the two other drugs induce remission. 
Aziathioprine and mercaptopurine have a slow onset of action and are therefore not 
adequate for induction. However for maintenance they are ideal.  Infliximab can be 
added to treatment with the immunosuppressive aziathioprine or mercaptopurine 
(Baumgart and Sandborn 2007). 
 
1.2.1.5.2.2. Surgery Treatment 
Surgical therapy is necessary if an intensive medical management in patients do not 
resort. A surgery does not cure patients with Crohn’s disease, yet it is often 
necessary for inducing remission. A part, or a complete bowel obstruction, internal 
fistulas, enterovesical fistulas and enterocutaneous fistulas are reasons for an urgent 
surgery (Baumgart and Sandborn 2007). 
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1.2.1.5.3. Composition and Differences to Normal Microbiota 
The faecal microbiota is stable in healthy humans considered individually, whereas in 
patients with Crohn’s disease a temporal instability is predominant. Studies showed 
that bacterial composition varied between remission and active disease (Seksik, 
Rigottier-Gois et al. 2003; Sokol, Lay et al. 2008). Furthermore the bacterial 
biodiversity is marked by a reduction. Firmicutes are reduced, in particular 
Faecalibacterium prausnitzii which is part of the Clostridium leptum group (Sokol, Lay 
et al. 2008). Giaffer et al. noted that E.coli is significantly increased in the faeces in 
patients with CD (Giaffer, Holdsworth et al. 1991; Sokol, Lay et al. 2008). 
Enterobacterial populations were found in each faeces of CD patients but in none of 
a healthy human (Seksik, Rigottier-Gois et al. 2003; Sokol, Lay et al. 2008). Analysis 
of the mucosa indicate that the bacterial load is increased, but the diversity is 
significantly reduced (Sokol, Lay et al. 2008). In other studies a distortion of the 
composition of Firmicutes has been previously described in IBD patients. The 
biodiversity in IBD patients was restricted in a trial which was conducted by 
Manichanh et al., mainly the C. leptum group. They also detected an association 
between Crohn’s disease and a decline of C. leptum group (Manichanh, Rigottier-
Gois et al. 2006; Sokol, Seksik et al. 2009). Faecalibacterium prausnitzii, which is 
part of the C. leptum group, was particularly reduced (Maidak, Cole et al. 2001; 
Martinez-Medina, Aldeguer et al. 2006; Sokol, Seksik et al. 2009). Many bacteria 
which are part of the Clostridium leptum group are butyrate producing bacteria. 
Butyrate possesses anti-inflammatory and immunmodulatory properties and is a 
major source of energy for colonocytes. Therefore butyrate might have a protective 
role for the mucosa (Segain, Raingeard de la Bletiere et al. 2000; Klampfer, Huang et 
al. 2003; Sokol, Seksik et al. 2009). A deficiency of the Firmicutes bacteria therefore 
might be a cause for disease development (Sokol, Seksik et al. 2009). 
Ott et al. investigated the microflora of the mucosa from patients with Crohn’s 
disease. The bacterial diversity was 50% reduced compared to that of healthy 
individuals. Especially a decline of anaerobic bacteria like Bacteroides species, 
Eubacterium species and Lactobacillus species were the result of the diseases (Ott, 
Musfeldt et al. 2004). Investigators have already determined a decrease in the 
amount and biodiversity of Firmicutes in patients with Crohn’s disease. Especially 
Faecalibacterium prausnitzii which is a subgroup of C.leptum is substantially 
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reduced. Crohn’s disease is caused by a defect of the immune system which is 
supposed to be triggered by a change in the composition of the intestinal microbiota. 
In a trial the mucosa associated microbiota of patients with Crohn’s disease was 
investigated after surgical resection and following 6 months thereafter. The results 
demonstrated that, patients who had lower counts of Faecalibacterium prausnitzii 
after surgery were predisposed for recurrence 6 months after surgery. That led to the 
conclusion that the lower abundance of Faecalibacterium prausnitzii was associated 
with the recurrence of the disease. The anti-inflammatory effect of Faecalibacterium 
prausnitzii might be the cause for patients who stayed in remission. Administration 
with Faecalibacterium prausnitzii could be a strategy in the treatment of CD patients 
(Sokol, Pigneur et al. 2008). 
Author CD Patients Healthy Individuals 
(Sokol, Lay et al. 2008) Bacterial diversity ↓ 
Firmicutes ↓ 
Faecalibacterium prausnitzii ↓ 
 
(Giaffer, Holdsworth et al. 
1991) 
E.coli ↑  
(Seksik, Rigottier-Gois et al. 
2003) 
Enterobacteria occurred only in 
the faeces of CD patients 
 No Enterobacteria 
(Manichanh, Rigottier-Gois et 
al. 2006) 
Bacterial diversity ↓ 
C. leptum ↓ 
 
(Maidak, Cole et al. 2001) Faecalibacterium prausnitzii ↓  
(Martinez-Medina, Aldeguer et 
al. 2006) 
Faecalibacterium prausnitzii ↓  
(Ott, Musfeldt et al. 2004) Bacterial diversity 50% ↓ 
Bacteroides ↓ 
Eubacterium ↓ 
Lactobacilli ↓ 
 
(Sokol, Pigneur et al. 2008) Faecalibacterium prausnitzii ↓  
 
Table 2. Summarized results from studies investigating the differences of microbiota in CD 
patients. 
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1.2.1.5.4. Probiotics and Counselling 
Nutrition during the active phase in patient’s with Morbus Crohn 
In addition to the normal diet, enteral nutrition is suitable for the acute phase. This 
enteral nutrition enables compensation of the deficiencies of vitamins, minerals and 
energy. If the patient is in worse condition, an exclusively enteral nutrition is 
recommended which should supply the needs of daily energy. Is the patient in the 
worst condition with its inflammation probably only parenteral nutrition may be 
helpful. In this case the entire gastrointestinal tract is circumvented due to an access 
over the blood system. The parenteral nutrition should last 2-4 weeks. General 
recommendations during the acute phase are a high consumption of beverages 
especially water and tea which can be enriched with salt to balance the loss of 
electrolytes. Small meals are recommended therefore 6-7 times over the day. Diet 
should not be fat free, but the amount of fat should be reduced. Enough consumption 
of proteins should also be assured. Lactose is very often not tolerated from patients 
during the active stadium and therefore yoghurts and products without lactose should 
be consumed. In the acute phase patients are recommended to avoid dietary fibers. 
Thereby resorption takes place in the upper part of the small bowel whereby the 
inflamed part is tranquilized (Schiener, Reiterer et al. 2008). 
Patients in remission 
In the remission, it is of high importance to compensate the developed deficiencies 
during the active phase. In the symptom free interval a diet which is rich of dietary 
fibers is crucial. After the active phase the gradual return to solid food has to take 
place slowly. First the enteral diet changes from fiber poor to fiber rich. After a start of 
tea, followed by white bread a transfer to gruels made of wholemeal, boiled rice, 
noodles, potatoes, and boiled vegetables; afterwards fruits in forms of compote, 
fatless poultry, fish and meat. The amount of fat should increase very slowly and in 
the last step cheese and snag can be added. Patients very often have individual 
intolerances, where a nutrition diary may help to detect individual intolerances. 
Nevertheless these intolerances are transient and after a few weeks most edibles are 
again compatible. Coffee should be avoided because it activates the peristaltic and 
therefore encourages diarrhea (Schiener, Reiterer et al. 2008). 
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Probiotics 
The current existing trials are promising that probiotics may have a therapeutic effect. 
Nevertheless larger controlled trials are needed before probiotics can be integrated in 
routine medical treatment (Sheil, Shanahan et al. 2007). General probiotic 
administration is not as successful in patients with Crohn’s disease like it is in 
patients with Ulcerative colitis, but a combination of VSL#3 and Saccharomyces 
boulardii have had a therapeutic effect (Reiff and Kelly 2009). Up until now results 
from several studies have not been consistent, especially that of the dose and the 
type of probiotics strains differing between the trials (Park and Floch 2007). 
Saccharomyces boulardii 
In a trial with CD patients after combined treatment with S.boulardii and mesalazine a 
clinical relapse occurred in 6.25% of patients, whereas in patients with only 
mesalazine treatment relapse occurred in 37.5% of patients (Guslandi, Mezzi et al. 
2000). Saccharomyces boulardii can improve but can not normalize the leaky gut in 
patients suffering from Crohn’s disease (Garcia Vilela, De Lourdes De Abreu Ferrari 
et al. 2008; Reiff and Kelly 2009). 
Lactobacilli 
In a study from Malin et al. treatment with Lactobacillus GG increased gut IgA levels, 
which could promote the gut immunological barrier (Malin, Suomalainen et al. 1996). 
Admittedly in a large study with paediatric patients who were administered with LGG 
combined with medical treatment had no improvement in comparison to a placebo 
group combined with medical treatment (Bousvaros, Guandalini et al. 2005). 
Administration with L. rhamnosus GG added to Prednisone and immunmodulatory 
drugs improved the condition of 4 children with mild to moderate disease activity 
already after 1 week and lasted throughout the study (6 months). In 3 of the patients 
a reduction of the steroid dose was possible and an improved gut barrier function 
was recognized (Gupta, Andrew et al. 2000). Nonetheless several trials exist which 
could not prove the beneficial effects of Lactobacilli in Crohn’s disease. In a trial with 
11 patients with active Crohn’s disease, patients were either administered with L. 
rhamnosus GG (LGG) or a placebo for 6 months. Before the beginning of the trial a 
reduction of the steroid amount was performed and antibiotics were applied. L. 
rhamnosus had not the ability neither to induce remission nor to maintain remission 
(Schultz, Timmer et al. 2004). Nearly similar results appeared with a study population 
who were in the stage after surgery. Administration with LGG for one year after 
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surgery showed no differences to the placebo group neither in symptomatic nor 
endoscopic recurrence (Prantera, Scribano et al. 2002).  The study form Marteau at 
al. showed similar results with Lactobacillus johnsonii which had no effect in 
preventing postoperative recurrence in comparison to the control group (Marteau, 
Lemann et al. 2006). 
VSL#3 
The effect of VSL#3 in combination with an antibiotic has also been investigated. 
VSL#3 is composed of Lactobacillus plantarum, Lactobacillus casei, Lactobacillus 
acidophilus, Lactobacillus delbrueckii spp. bulgaricus, Bifidobacterium infantis, 
Bifidobacterium breve, Bifidobacterium longum and Streptococcus salivarius 
thermophilus (Sheil, Shanahan et al. 2007). Forty CD patients who previously had a 
surgery received either rifaximin for 3 months, followed by VSL#3 for 9 months or 
mesalazine for 12 months. 20% of those who were in the probiotic group had a 
relapse, whereas a relapse occurred in 40% of the CD patients who were part of the 
mesalazine group (Campieri, Rizzello et al. 2000). 
E.coli Nissle1917 
Although it was a small pilot study and therefore the results were not statistically 
significant, treatment with E.coli Nissle1917 reduced the relapse rate in comparison 
to the placebo group. From 12 patients in the E.coli group, 33% had a relapse 
whereas from the 11 patients in the control group 63% were affected by a relapse 
(Malchow 1997). 
 
In summary these results show that up until now results are inconsistent and just 
treatment S. boulardii showed to have effectiveness in several studies (Park and 
Floch 2007). 
 
1.2.1.5.5. Modern Molecular Findings, Probiotics 
Thus far, none of the available studies have found a beneficial effect of probiotics for 
patients with Crohn’s disease.  Lactobacillus rhamnosus GG (LGG) had no positive 
impact either in reduction of severity of recurrent lesions, nor in inhibiting endoscopic 
recurrence (Prantera, Scribano et al. 2002; Reiff and Kelly 2009). Saccharomyces 
boulardii is at the moment the only probiotic which has a positive impact for patients 
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with Morbus Crohn. It improved the leaky gut but it could not normalize it (Garcia 
Vilela, De Lourdes De Abreu Ferrari et al. 2008; Reiff and Kelly 2009). 
So far it is not known which probiotic strain, which dose, which mode of 
administration is suitable and how long a therapy should be conducted (Sheil, 
Shanahan et al. 2007). 
 
 
1.2.2. Obesity 
Obesity and its associated metabolic disorders have become a major public health 
issue worldwide. Obesity is seen ass an illness with multicourse factors. Alongside 
environmental factors, genetic predisposition and individual behaviour, investigators 
have found that epigenetic factors indeed play a role (Campion, Milagro et al. 2009). 
A positive energy balance is seen as the chief cause for obesity, but the nutrition in 
early childhood also seems to have significance in this illness. Formula or formula 
mixed fed infants seem to be a reason for increased susceptibility for obesity, 
whereas breastfeeding seems to be a protective factor (Nadal, Santacruz et al. 
2009). Also the birth process is determining; a natural birth should be preferred to a 
caesarean section (Kalliomaki, Collado et al. 2008). 
 
1.2.2.1. Clinical Picture 
A positive energy balance which leads to a state of chronic, low-grade inflammation 
with an abnormal cytokine production and acute-phase inflammatory protein 
production is characteristic of obesity (Nadal, Santacruz et al. 2009). 
Many obesity related disorders increase type 2 diabetes mellitus, cardiovascular 
disease, pulmonary hypertension, obstructive sleep apnoea, gastrooesophageal 
reflux disease and musculoskeletal disorders, just to name only a few. Obesity is also 
the cause for psychosocial problems, and a variety of cancers. An increased risk of 
mortality is also associated with obesity (DiBaise, Zhang et al. 2008). 
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1.2.2.2. Therapy 
The primary goal of obesity- therapy is a stable weight reduction which is possible 
due to negative energy balance. Therefore a change in diet behaviour as well as in 
exercise behaviour is essential. A continuous weight reduction over a long period is 
preferable, compared to fast weight reduction.  Due to a decreased food intake it is 
important to consume nutrient rich products to assure an adequate supply of 
essential nutrients. Besides the change in diet there is also the alternative of 
additional administration with different medicaments to decrease weight, such as 
thyroid hormones, anoretica, lipase inhibitors, fat-subsitutes or diuretica. These drugs 
can support weight reduction, although a change in behaviour is inevitable. 
Psychotherapy can support individuals as well in their weight reduction. There is also 
the possibility for an operative intervention but this should be seen as the last resort 
and is only advisable in patients with severe obesity (Elmadfa and Leitzmann 2004). 
 
1.2.2.3. Composition and Differences to Normal Microbiota 
1.2.2.3.1.  Studies with mice 
In obese mice the percentage of Bacteroidetes is lower than in lean mice, whereas 
the Firmicutes amounts are in obese mice higher than in lean mice. Due to weight 
loss Ley et al. recognized an increase in Bacteroidetes and a decline of Firmicutes 
(Ley, Backhed et al. 2005). Ley et al. analyzed the 16SRNA sequences from cecal 
microbiota of genetically obese (ob/ob) mice, their lean ob/+ and +/+ siblings and 
their ob/+ mothers. All received the same polysaccharide-rich diet. Remarkable was 
the fact that, ob/ob mice had 50% fewer Bacteroidetes and correspondingly more 
Firmicutes than their lean littermates. In addition they discovered a link between 
kinship and distal gut microbial diversity, but the differences in obese mice existed 
independent of kinship and sex (Ley, Backhed et al. 2005; DiBaise, Zhang et al. 
2008). Turnbaugh et al. wanted to figure out how the gene content in the gut 
microbiota contributed to obesity. They analyzed the distal gut microbiota in obese 
and lean mice. In obese mice the ratio of Firmicutes to Bacteroidetes were increased 
compared to their lean littermates. The amounts of Archaea were also higher in 
obese mice compared to the lean ob/+ and +/+ littermates. The microbiota of obese 
mice included genes which encoded enzymes that broke down otherwise indigestible 
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dietary polysaccharides. In the faeces they found more end products of fermentation 
and fewer calories, which lead to the assumption that the gut microbiota lead to a 
facilitation of calorie extraction from indigested food. The major end products butyrate 
and acetate were increased. This was a logical conclusion because Firmicutes are 
butyrate producer (Turnbaugh, Ley et al. 2006; DiBaise, Zhang et al. 2008). 
Finally they wanted to show that the gut microbiota is the determining factor and so 
they transferred the gut microbiota of either obese or lean mice to gnotobiotic lean 
mice. The results were that after two weeks, gnotobiotic mice which received the gut 
microbiota from obese mice, extracted more calories from food and also showed a 
significant higher fat gain than the mice with the lean microbiota. These findings lead 
to the conclusion, that gut microbiota indeed plays an important role in the 
pathogenesis of obesity (Turnbaugh, Ley et al. 2006; DiBaise, Zhang et al. 2008). 
The interaction between bacteria and Archaea in the gut may also be an important 
factor in increased energy extraction. As a result of the Archaeal methanogenesis the 
production of hydrogen and other reaction products is inhibited. Acetate and butyrate 
produced by the bacteria in the gut are not oxidized and the amount of the production 
can increase if the Archaea help to remove hydrogen and formate. Acetate and 
butyrate are important carbon sources for the epithelium cells in the colon. Thus this 
syntrophism leads to an increased energy extraction from indigestible 
polysaccharides and might be a factor in obesity regulation (DiBaise, Zhang et al. 
2008). 
Bacteroides thetaiotaomicron is highly efficient in glycan metabolism, metabolizes 
indigestible sugars and therefore harvests additional energy (Comstock and Coyne 
2003; DiBaise, Zhang et al. 2008). Methanobrevibacter smithii makes up 10% of the 
anaerob microbiota in the human colon of healthy individuals (Macfarlane and 
Macfarlane 1997; DiBaise, Zhang et al. 2008). Consequently Samuel and Gordon 
conducted an experiment with mice in which they colonized the gut of these mice 
with common colonic bacteria either with Bacteroides thetaiotaomicron or 
Methanobrevibacter smithii or both. The increase of adiposity after colonization with 
bacteria and Archaea was higher than colonization with just one of the two. In 
addition the investigators discovered that M. smithii influenced the metabolism of B. 
thetaiotaomicron by influencing it to consume mainly fructose containing 
polysaccharides breaking down in several substances, but also formate which is an 
important energy source for M. smithii. This detection leads to the hypothesis that the 
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synergism between microorganisms indeed plays an important role in energy 
homeostasis. M. smithii might be a therapeutic target for obese patients, however 
further studies are needed (Samuel and Gordon 2006; DiBaise, Zhang et al. 2008). 
In a series of experiments Backhed et al. reasoned that young conventionally reared 
mice have a 40% higher body fat content and 47% gonadal fat content than germ 
free mice, although the germ free mice consumed more food than the conventional 
mice. After these findings they transplanted the distal gut microbiota from the 
conventional mice into the gnotobiotic mice. In conclusion the gnotobiotic mice had a 
60% increase of body fat within two weeks even though the food consumption and 
the energy expenditure were stable. These findings lead to supporting the 
assumption that the composition of the microbiota has an impact on the energy 
extraction from the diet. Besides the increase in body fat, insulin resistance, 
adipocyte hypertrophy and increased levels of circulating leptin and glucose 
appeared (Backhed, Ding et al. 2004; DiBaise, Zhang et al. 2008). 
In another experiment Bäckhed et al elucidated the fat storage of fatty acids into 
adipocytes with the help of germ-free mice (gnotobiotic). A comparison between 
conventionally raised mice and the gnotobiotic mice was conducted. The 
conventional mice had 42% more body fat than the germfree mice although the food 
intake was 29% less than the food intake of the germ free mice. After these findings 
the authors conventionalized some germfree mice. After 14 days an increase of 57% 
in body fat, a 61% increase of epidemical fat and a 7% decrease of lean body mass 
became apparent. The serum triglycerides did not change (Backhed, Manchester et 
al. 2007). 
Bacteroides and Clostridia were the most common species in the mouse cecum and 
therefore investigators choose B. thetaiotaomicron for the conventionalization for 
over 2 weeks. B. thetaiotaomicron is rich of glycosylhydrolases and therefore 
responsible for degradation of plant polysaccharides. A significant increase in total 
body fat was the consequence. The oxygen consumption was an indicator for the 
metabolic rate and was therefore measured. The metabolic rate was 27% lower in 
the leaner germfree mice in comparison to the 14-day conventionalized mice. The 
results were unexpected for the authors and therefore they measured the 
tricarboxylic acid cycle and assessed that a significant increase in citrate, 
ketoglutarate and malate was distinctive for the tissues of conventionalized mice in 
comparison to the germ free mice. Curiously the conventionalized and the germfree 
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mice had the same stores of energy compounds. Investigators assume that 
conventionalized mice have an inefficient metabolism and in conclusion an increased 
body fat storage. Beside this, conventionalized mice have a higher insulin resistance 
and evaluated circulating leptin and glucose levels. Shortly after the germ-free mice 
became conventionalized, an increase in adipocyte size appeared, but not an 
increase in adipocyte number. After the first conventionalization of germ-free mice, 
the lipoprotein lipase activity increased about 122% in epidemical fat pads and 99% 
ascent in heart tissue. Increased triglyceride levels were the consequence due to an 
increased lipoprotein lipase activity which led to elevated fatty acid uptake. 
Angiopoietin-like protein-4 (Fasting induced adipocyte factor = Fiaf) was high in 
germ-free mice and suppressed lipoprotein lipase, whereas after conventionalization 
a suppression of Fiaf by the gut microbiota occurred. This Fiaf suppression led to 
increased lipoprotein lipase activity (Backhed, Ding et al. 2004; DiBaise, Zhang et al. 
2008). 
 
1.2.2.3.2.  Studies with humans 
Ley et al. analyzed the fecal gut microbiota continuously in 12 obese patients during 
a weight loss programme for the duration of one year. In this experiment one group 
received a fat restricted diet and another group consumed a carbohydrate-restricted 
low calorie diet. Before the start of the administered diet all of the obese patients had 
higher levels of Firmicutes and lower levels of Bacteroidetes than the lean control 
group. After the weight loss the amount of Bacteroidetes increased while the levels of 
Firmicutes decreased; these levels correlated with the percentage of weight loss and 
not with the chances in dietary caloric content. Before the weight loss Bacteroidetes 
made up 3% of the gut bacteria and 15% after the weight loss. Until now it is not 
known why obese people have more Firmicutes. Firmicutes have a vast diversity and 
therefore may be able to have a more efficient energy extraction which contributes to 
an easier fat storage (Ley, Turnbaugh et al. 2006; DiBaise, Zhang et al. 2008). 
In another experiment taken by French investigators, results presented that obese 
patients had a bacterial profile poor in Bacteroidetes and rich in Lactobacillus. The 
obese/lean ratio of Methanobrevibacter smithii accounted 1.72. The increased 
amount of Lactobacillus in obese patients supports the assumption that Lactobacillus 
plays a role in weight gain. Interestingly, they also elevated the bacterial composition 
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of anorexic patients. These patients had the highest amounts of Methanobrevibacter 
smithii, whereas all the other bacterial profiles where similar to those of the lean 
patients. An explanation could be that M. smithii lead to a superior exploitation of 
energy which is the result of a very low caloric diet. Another explanation by the 
authors was that Methanobrevibacter could be related to constipation, which is a 
common phenomenon in anorexia nervosa patients (Armougom, Henry et al. 2009). 
In a study conducted in 2008 the investigators sought to elucidate if there was an 
association between the gut microbiota in early childhood and weight development in 
the following years. This study was based on a previous study from 2001. 25 obese 
and overweight children and 24 normal weight children were selected and the BMI of 
these children at the age of 7 was determined. The microbiota of the faeces in the 6 
and 12 month was analyzed. The results showed that normal weight children had 
significantly more Bifidobacteria than the obese children. The contents of S. aureus 
were numerously lower in normal weight children than in obese children (Kalliomaki, 
Collado et al. 2008). 
In a study taken in 2009 the composition of the gut microbiota was analyzed in 9 
individuals. Three of them had normal weight, three were morbidly obese and 3 had 
a gastric bypass. The faeces were analyzed in the group with the gastric bypass 8 
and 15 months after the surgery. In this time one of these three individuals stopped 
losing weight. In the overall analysis of the gut microbiota, the investigators detected 
6 main bacterial phyla. Firmicutes and Bacteroidetes made up the major content. 
Beside of these two, Proteobacteria, Actinobacteria, Fusobacteria and 
Verrucomicrobia occurred. The results showed that obese patients had increased 
levels of Archaea, in contrast to the normal weight individuals, who contained no 
Archaea and just one of the three gastric bypass patients had small amounts. 
Although the Bacteroidetes number was not significantly higher in obese patients, 
Prevotellaceae, a subgroup of Bacteroidetes was significantly increased in obese 
patients. Prevotellaceae is a group which has members who are carbohydrate- and 
protein-fermenting and acetate and H2 producers. The conclusion of this study was 
that the gut of obese patients contained increased amounts of H2 producing bacteria 
particularly the Prevotellacea family and some members of the Firmicutes (Zhang, 
DiBaise et al. 2009). Admittedly, this study could not support the results from Ley et 
al. In the study from Ley et al. obese patients had lower amounts of Bacteroidetes 
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and proportionally more Firmicutes than lean individuals (Ley, Turnbaugh et al. 
2006). 
In a study from Nadal et al. investigators wanted to assess the effects of calorie 
restriction and exercise on the faecal microbiota and the immunoglobulin-coating 
bacteria in obese/overweight adolescents. Within 10 weeks the participants were 
instructed to have a calorie restricted diet as well as perform increased physical 
activity. After the 10 weeks the patients were divided into groups depending on their 
weight loss. Group A, which lost more than 4kg, and group B with those whose 
weight loss was below 2.5kg. Within participants of group A the weight reduction 
resulted in a significant decrease of Gram positive Clostridium hystolyticum, 
Clostridium lituseburense and E. rectale-C. coccoides proportions. The decrease 
correlated with the loss of body weight. In contrast the Gram negative Bacteroides-
Prevotella levels significantly increased. Lactobacillus-Enterococcus proportions, 
Enterobacteriaceae, E. coli, and Roseburia groups increased but not in high 
amounts. The decrease of Bifidobacteria and sulphate reducing bacteria was not 
significant and therefore not relevant. In group B, in which the weight loss was low, 
none of the bacteria showed significant differences. Nevertheless the biochemical 
parameters changed in group B. Serum glucose was slightly changed and serum 
HDL-cholesterol values were higher than before the intervention. After the 
intervention Group A had a significant reduction in fecal energy content in contrast to 
group B. Some biochemical parameters changed in group A after the intervention. A 
significant decline of serum glucose and total cholesterol concentration was the 
consequence after the intervention. This decline correlated with changes in the 
enteric group proportions as well as with changes in total gram negative bacteria. 
LDL cholesterol was reduced after the intervention but not significantly (Nadal, 
Santacruz et al. 2009). 
IgA coating bacteria are an indicator for low grade inflammation. Before the 
intervention IgA coating bacteria where higher than after the 10 weeks. The drop of 
IgA coating bacteria was associated with decrease of E.rectale-C. coccoides and C. 
hystolyticum. The explanation for the correlation between these bacteria might be 
that the reduction of this butyrate producing bacteria leads smaller butyrate levels. In 
conclusion the immune cells have a reduced energy amount and can therefore 
produce less IgA –producing cells and in succession the IgA concentration falls. For 
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that reason considerations that weight loss depends on the diet and the gut 
microbiota must not be excluded (Nadal, Santacruz et al. 2009). 
Author Obese 
(Ley, Backhed et al. 2005) Bacteroides ↓  
Firmicutes ↑ 
(Turnbaugh, Ley et al. 2006) Firmicutes: Bacteroides ratio ↑ 
(Armougom, Henry et al. 2009) Lactobacilli ↑ 
(Kalliomaki, Collado et al. 2008) Bifidobacteria ↓ 
(Zhang, DiBaise et al. 2009) Archaea and Prevotellaceae ↑ 
(Nadal, Santacruz et al. 2009) After Weight reduction: 
Clostridium hystolyticum ↓ 
Clostridium lituseburense ↓ 
E. rectale-C.coccoides ↓ 
Bacteroides ↑ 
Lactobacilli ↑ 
Enterobacteriaceae ↑ 
E.coli ↑ 
Roseburia ↑ 
 
Table 3. Summarized results from studies investigating the differences of microbiota in obese 
individuals. 
 
 
 
1.2.2.3.3. Modern Molecular Findings, Mechanisms of Microbiota 
The microbiota comprises a number of interrelate mechanisms for energy regulation.  
(1) The first mechanism is the fermentation of indigestible dietary polysaccharides 
to absorbable forms. 
(2) The second mechanism is the intestinal absorption of monosaccharides and 
short chain fatty acids with their subsequent conversion to fat within the liver. 
(3) Finally the third mechanism is the regulation of host genes that promote 
deposition of fat in the lipocytes. 
(DiBaise, Zhang et al. 2008) 
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Figure V.  Mechanisms by which the intestinal microbiota may contribute to obesity.  
AMPK = adenosine monophosphate-activated protein kinase; ChREBP = carbohydrate response 
element binding protein; Fiaf = fasting induced adipocyte factor; LPL = lipoprotein lipase; LPS = 
lipopolysaccharide; PGC-1α = peroxisome proliferator-activated receptor γ coactivator 1α; SREBP-1 = 
sterol response element-binding protein type 1. 
(DiBaise, Zhang et al. 2008) 
 
 
 
Metabolic efficiency and energy recovery is individually different and therefore a 
possible explanation why some obese patients do not seem to overeat. The gut 
microbiota, can on the one hand, influence energy harvest from dietary substances 
and on the other hand affect genes that regulate the energy expenditure and storage 
(DiBaise, Zhang et al. 2008). 
ARCHAEA 
H2 is an end product of bacterial fermentation, which by accumulation reduces the 
efficiency of processing dietary polysaccharides (Stams 1994; Gill, Pop et al. 2006). 
Methanogenic-Archaea oxidizes H2. An increased amount of methanogenic-Archaea 
leads to an easier fermentation of plant polysaccharides and dietary fibers of H2 
producing fermenters, such as Prevotellaceae and in conclusion to an increased 
SCFA production. The SCFA are taken up through the epithelium of the human 
intestine which leads to the assumption that there is an association between Archaea 
and increased energy harvest (Zhang, DiBaise et al. 2009). 
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FIAF 
Investigators have found that the gut microbes suppress the intestinal fasting induced 
adipocyte factor (Fiaf) which is also known as angiopoetin-like protein 4. Fiaf is a 
lipoprotein lipase inhibitor (LPL). Through suppression of Fiaf the activity of the 
Lipoprotein Lipase increases and in succession influences the import and storage of 
triglyceride-derived fatty acids in adipocytes. In a study with mice the investigators 
induced a Fiaf suppression which led to an increased lipoprotein lipase activity and 
resulted in elevated fat storage (Backhed, Ding et al. 2004). 
In a study from Backhed et al. germ-free mice who consumed a Western-style, high 
fat, sugar rich diet were investigated. These mice were protected from obesity by two 
mechanisms: 
1. Because of the increased Fiaf levels the production of peroxisome proliferator-
activated receptor-γ coactivator was induced. Peroxisome proliferator-
activated receptor-γ coactivator is known to elevate the gen expression which 
encodes regulators of mitochondrial fatty acid oxidation. 
2.  Furthermore a protection from obesity by an increased activity of the enzyme 
adenosine monophosphate-activated protein kinase. This enzyme controls 
cellular energy status. 
(Backhed, Manchester et al. 2007; DiBaise, Zhang et al. 2008) 
 
 
Figure VI. Schematic view of how the gut microbiota effects host fat storage. 
The microbiota act through Fiaf to coordinate increased hepatic lipogenesis with increased lipoprotein 
lipase (LPL) activity in adipocytes, thereby promoting the storage of calories from the diet into Fiaf. 
(Backhed, Ding et al. 2004) 
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Cani et al. described a mechanism linking microbiota with obesity (Cani, Amar et al. 
2007; DiBaise, Zhang et al. 2008). This mechanism is based on the fact that obesity 
and insulin resistance is associated with low-grade chronic systemic inflammation 
(Wellen and Hotamisligil 2005; DiBaise, Zhang et al. 2008). The investigators 
assume that gram negative bacteria which reside in the gut provide 
lipopolysaccharides (LPS). The LPS act as a triggering factor linking inflammation to 
high fat diet –induced metabolic syndrome. They conducted various experiments with 
mice receiving a high-fat diet, which led to increasing levels of endotoxemia, and in a 
row a reduction of predominant bacterial population in the gut. Gram positive as well 
as gram negative bacteria were reduced, but favouring an elevation in gram negative 
to gram positive ratio. The chronic metabolic endotoxemia induces obesity, insulin 
resistance and diabetes (Cani, Amar et al. 2007; DiBaise, Zhang et al. 2008). In an 
experiment from Wright et al. CD14 mutant mice received a high-fat diet, showing 
that the metabolic endotoxemia induced the expression of inflammatory cytokines 
due to a CD14 dependent mechanism. The LPS bind at the surface of the innate 
immune cells, leading to a secretion of pro-inflammatory cytokines by CD14 (Wright, 
Ramos et al. 1990; DiBaise, Zhang et al. 2008). Due to human studies, it exists the 
assumption that the tone of insulin sensitivity is set by LPS/CD14 system and that 
this system furthermore regulates the onset of obesity and diabetes. Humans 
received the antibiotic polymyxin B which targets gram negative organisms and 
therefore reduces LPS expression and hepatic steatosis (Pappo, Becovier et al. 
1991; DiBaise, Zhang et al. 2008). A study from 2006 came to the finding that 
patients with type 2 diabetes had higher LPS levels than the control group without 
diabetes (Creely, McTernan et al. 2007; DiBaise, Zhang et al. 2008). 
 
Another assumption would be that a high fat diet is the cause for changes in gut 
microbiota and not conversely, that the gut microbiota is the cause for gaining weight. 
Host phenotype, genotype, immune function and diet impair the composition of the 
gut microbiome. In an experiment investigators consulted knockout mice with the 
phenotype RELMβ to elucidate the importance of these factors. At the beginning of 
the study the knockout mice and wild mice were fed with a normal chow diet and 
were therefore lean. After switching to a high-fat diet the wild mice had an increased 
weight gain, whereas the knockout mice remained lean. Due to the switch to high fat 
diet changes in the microbiota compositions occurred. A decrease of Bacteroidetes 
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and an increase of Firmicutes and Proteobacteria appeared in both genotypes. This 
showed that a high-fat diet leads to alterations in microbiota and not weight gain 
(Hildebrandt, Hoffmann et al. 2009). 
 
1.2.2.4. Probiotics and Counselling 
1.2.2.4.1. Prebiotics 
The colonic bacteria ferments prebiotic agents like fructo oligosaccharide and thus 
modulates the growth of colonic bacteria. The prebiotics are not digested in the upper 
gastrointestinal tract and have several functions in the gut (Gibson, Beatty et al. 
1995; Roberfroid 2002; DiBaise, Zhang et al. 2008). Recently two studies were 
conducted in which rats received a standard (Cani, Dewever et al. 2004) or a high fat 
(Cani, Joly et al. 2006) diet with addition of oligofructose (DiBaise, Zhang et al. 
2008). The findings of this study were controversial to previous studies because the 
oligofructose caused a reduced energy intake and consumption, and protected 
against weight gain. The specific modulation of the gut microbiota as well as other 
physiological effects of fibers like the increased satiety because of slower gastric 
emptying might be explanations for these contradictions. A single-blind cross-over 
study over two weeks with 10 healthy individuals with normal weight found that the 
satiety after breakfast and dinner was increased because of oligofructose and 
therefore led to a 5% reduced energy uptake in contrast to the placebo group (Cani, 
Joly et al. 2006; DiBaise, Zhang et al. 2008). Cani et al. noticed in a recent study that 
an increase of oligofructose led to an ascent of Bifidobacterial contents in high-fat-
diet mice. The amount of Bifidobacteria correlates negatively with endotoxemia. 
Furthermore Bifidobacteria positively influences the glucose tolerance, glucose 
induced insulin secretion and normalizes the inflammatory tone. Therefore prebiotic 
supplementation might be a relevant target in the therapy of obese patients, but 
further studies are needed (Cani, Neyrinck et al. 2007; DiBaise, Zhang et al. 2008). 
 
1.2.2.4.2. Probiotics 
Lactobacillus rhamnosus PL60 promises antiobese effects according to the study 
from Lee et al. This bacterium generates conjugated linoleic acid in diet-induced 
obese mice. Animal studies detected that beside other positive health functions, 
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linoleic acid reduces body fat. In an 8 week experiment in which mice received L. 
rhamnosus PL60 a weight reduction occurred without reducing the energy intake of 
the mice (Lee, Park et al. 2006; DiBaise, Zhang et al. 2008). In further studies the 
explanations for these effects were investigated. The anitobesity effects can be 
related to the apoptosis and messenger RNA expression in the white adipose tissue. 
How relevant L. rhamnosus for energy reduction in humans is doubtful because L 
rhamnosus reduces the cell numbers of adipose tissue but not the cell size. In adults 
the cells numbers are constant and just the size can change after weight gain. It is 
not evident if L. rhamnosus would be a therapeutic target in obesity treatment 
(DiBaise, Zhang et al. 2008). 
A study with 122 obese humans aggravated the fact that L. rhamnosus is not 
adequate for weight reduction. In the randomized controlled trial the patients were 
treated with 3.4g conjugated linoleic acid or placebo for one year and it had no effect 
(Larsen, Toubro et al. 2006; DiBaise, Zhang et al. 2008). 
In another experiment from Sonnenburg et al, germfree mice received B. 
thetaiotaomicron and Bifidobacterium longum which led to an increase in the 
polysaccharide range targeted for degradation. Similar results appeared in a probiotic 
administration with Lactobacillus casei (Sonnenburg, Chen et al. 2006; DiBaise, 
Zhang et al. 2008). Martin et al. found that a probiotic administration resulted in 
distinct changes of the microbiome accompanied by alterations of the metabolism in 
the tissue concerning energy, lipid and amino acid metabolism (DiBaise, Zhang et al. 
2008; Martin, Wang et al. 2008). 
 
Many questions have to be clarified before it is possible to determine if differences in 
the gut may lead to different weight in humans. It has to be determined if the 
alterations in the gut are the cause or the result for obesity. Also hormones and other 
signals and their influence on the composition of the microbiota must be regarded. 
Besides the understanding of the relative proportions of Firmicutes, Bacteroidetes 
and Archaea in mice and humans have to be elucidated. The environmental as well 
as the genetic factors of each individual must also be regarded, but also the surface-
adherent differences of the microbiota in the mucosa must be elucidated for obese 
and person who already lost weight (DiBaise, Zhang et al. 2008). 
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1.2.2.4.3. Modern Molecular Findings, Probiotics 
Obese persons have another composition of the microflora than lean persons. 
Gnotobiotic lean mice received the gut flora of obese mice and an increase in weight 
was the succession.  Lactobacillus gasseri, Lactobacillus reuteri, Lactobacillus 
acidophilus appear to have a cholesterol reducing function by assimilation of 
cholesterol. L.gasseri inhibits the rear resorption of bile acids in the terminal ileum 
and this leads to an increased excretion of acid steroids with the stool. 
Undoubtedly the reduction of lipids is only proven in animal experiments and needs 
further investigation, especially on humans (Schulze, Sonnenborn et al. 2008). 
In further studies the explanations for these effects were investigated. The 
anitobesity effects can be related to the apoptosis and messenger RNA expression in 
the white adipose tissue. How relevant L. rhamnosus for energy reduction in humans 
is doubtful because L rhamnosus reduces the cell numbers of adipose tissue but not 
the cell size. In adults the cells numbers are constant and just the size can change 
after weight gain. It is not evident if L. rhamnosus would be a therapeutic target in 
obesity treatment (DiBaise, Zhang et al. 2008). 
 
 
1.2.3. Atopic Disease 
In westernized countries the frequency of atopic diseases increased in the last years. 
Especially eczema, food allergy, hay fever and asthma are common disorders. 
Because it is clear that not only the genetic make up is the cause, environmental 
factors must indeed play an important role (Asher and Weiland 1998; Nowak, Suppli 
Ulrik et al. 2004; Penders, Stobberingh et al. 2007). Strachan’s observations were 
that, children with more siblings as well as children growing up in rural regions are 
not as susceptible for atopic diseases like children from urban regions and children 
with fewer siblings (Strachan 1989; Strachan 2000; Karmaus and Botezan 2002; 
Penders, Stobberingh et al. 2007).  Hospital deliveries, caesarean sections, smaller 
family size, the use of antibiotics, good hygiene, and differences in the maternal diet 
lead to changed exposure of bacteria for children (Brandtzaeg 2002; Gore, Munro et 
al. 2008).  A protection of allergies might be the infections of gastrointestinal 
pathogens (Matricardi, Rosmini et al. 2000; Wang, Karlsson et al. 2008). 
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The bacterial colonisation is decelerated in infants from industrialized countries in 
comparison to children living in developing countries (Adlerberth, Carlsson et al. 
1991; Adlerberth, Strachan et al. 2007). Hence their immune system is less 
stimulated (Shroff, Meslin et al. 1995; Adlerberth, Strachan et al. 2007). Neonates 
who developed allergies seem to have an altered colonisation of their microbiota 
(Bjorksten 2004; Prescott and Bjorksten 2007). 
 
1.2.3.1. Clinical Picture 
Asthma bronchiale, atopic dermatitis, allergic rhinitis and conjunctivitis as well as 
Urticaria and IgE-mediated food and medication allergy belong to the generic term 
atopic diseases (Renz-Polster and Krautzig 2008). 
Atopic diseases are chronic inflammatory disorders. The cause is an aberrant 
immune response against common harmless environmental antigens (allergens) in 
susceptible individuals. More precisely alterations in T-helper 2 cells are the cause 
(Romagnani 2006; Penders, Stobberingh et al. 2007). These T helper cells type 2 
produce proinflammatory cytokines like IL-4, IL-5 and IL-13 which trigger IgE 
production and eosinophila. Under “normal” conditions the Th1, Th3 and T regulatory 
cells counteract due to their production of other cytokines, which is initiation is 
partially triggered by the intestinal microbiota (Rautava, Kalliomaki et al. 2005; 
Isolauri, Kalliomaki et al. 2008).    
Atopic dermatitis 
Is one of the most frequent allergic skin diseases and the incidence is ascending 
(Renz-Polster and Krautzig 2008). It is a pruritic chronically relapsing inflammatory 
skin disease which is the portal for other sensitizations (Hanifin 2002; Isolauri, 
Kalliomaki et al. 2008). 
Urticaria 
Is mostly idiopathic but can also be an IgE-mediated reaction due to environmental 
factors like coldness, compression, heat, cholinergic or adrenergic stimulation. It is 
characterized by pruritus, erythem and quaddels on the skin (Renz-Polster and 
Krautzig 2008). 
Asthma bronchiale 
It’s the most common chronic inflammation disease in humans. The most triggering 
factors are house dust mites, mildew spores, allergens from cats and pollen. It is 
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characterized by acute dyspnoea and obstruction of the lower air passages. The 
obstruction is caused by mucus swelling due to inflammation, bronchia construction 
as well as dyscrinie  (Renz-Polster and Krautzig 2008). 
Allergic rhinitis 
Manifestation incidences in childhood, although with increasing age in most cases 
the symptoms alleviate. Major causes for the symptoms are pollen. Half of the 
persons with allergic cold, develop asthma bronchiale after 8 years (Müller 2006). 
Allergic rhinoconjunctivitis 
Pruritus and sneezing, watery rhinorrhea, obstructed nose, light sensibility and 
swollen lids are the main symptoms. General symptoms are headache, fatigue, 
exhaustion, increased thirst and minimized productivity (Müller 2006).  
Food allergy 
Can arise in each state of age, but occur in most cases in the first two months of life. 
The absence of an intact barrier function in the gastrointestinal tract is the cause. 
Cow milk allergens are the important agents in development (Müller 2006).  
 
1.2.3.2. Therapy 
The most important issue which should always be kept in mind is allergen 
elimination. In the case of a medication allergy it is easier than in the case of a food 
allergy or house dust mites. Hence a medical prophylaxis is necessary in many 
cases. If medical prophylaxis does not avoid the occurrence of symptoms the 
treatment with antihistaminic drugs is helpful to dampen the first reaction. Due to 
glucocorticoides the following inflammatory reactions can be stopped  (Renz-Polster 
and Krautzig 2008). 
 
1.2.3.3. Composition and Differences to Normal Microbiota 
While Bifidobacteria and Lactobacilli seem to be reduced in individuals who are 
susceptible for atopic diseases, Clostridia, Enterobacteriaceae and Staphylococci 
might be the cause for the development of the disease (Penders, Stobberingh et al. 
2007). In children who have developed allergy within their first two years of life, 
Bjorksten et al. noticed a decreased colonisation of Enterococci, Bifidobacteria and 
Bacteroides, whereas the amount of Staphylococcus aureus was increased in faeces 
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(Bjorksten, Naaber et al. 1999; Bjorksten, Sepp et al. 2001; Songjinda, Nakayama et 
al. 2007). He et al. found out that the composition of Bifidobacteria differs between 
allergic and non-allergic children. While allergic children had high amounts of 
Bifidobacterium adolescentis similarly to adults, non-allergic children had increased 
amounts of Bifidobacterium bifidum (He, Ouwehand et al. 2001; Shreiner, Huffnagle 
et al. 2008). Clostridium difficile seems to play an important role in atopic infants.  In 
recurrent wheezy infants IgG levels, which are characteristic for Clostridium difficile 
were significantly increased in comparison to non-wheezy infants (Woodcock, Moradi 
et al. 2002; Shreiner, Huffnagle et al. 2008). 
Fact is, that due to different study designs, differences of the investigated microbes, 
different methods and different outcomes it is difficult to compare the studies 
(Penders, Stobberingh et al. 2007). Furthermore it is until now not clear if the 
alternated microbiota in early childhood persists in preschool age (Sepp, Julge et al. 
2005; Stsepetova, Sepp et al. 2007). 
 
Wang et al. investigated the 1 week old faeces of 15 remarkable atopic and 20 
healthy children from a previous study project, namely ALLERGYFLORA. Within this 
project investigators assessed the bacterial colonisation of 318 Swedish, British and 
Italian infants, but could not find significant differences in colonisation between 
infants with atopic eczema or without atopic eczema during the first 18 months of life 
(Adlerberth, Strachan et al. 2007; Wang, Karlsson et al. 2008). Nevertheless Wang et 
al. found that that the diversity was significantly lower in children who developed 
atopy later, in comparison to children who stayed healthy during their first 18 months 
of life. The authors came to the conclusion that a high diversity of microbiota might 
be a preventive factor for the development of atopic diseases (Wang, Karlsson et al. 
2008). 
 
If the gut microbiota is less diverse, special species have the chance to enforce 
which might have detrimental consequences for development of allergic diseases. 
Clostridium difficile is an example. Pender et al. concluded that an increased amount 
of Clostridium difficile occurred especially in children who developed atopic diseases 
(Penders, Thijs et al. 2007). Sjögren et al. did not come to such results, in contrary 
the opposite was the case. Children who developed allergic diseases were not 
colonized with Clostridium difficile during their first 2 months of life (Sjogren, 
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Jenmalm et al. 2009). However several other studies exist which concluded that 
increased appearance of Clostridia was accompanied by lower diversity of other 
bacteria which resulted in allergies (Bottcher, Nordin et al. 2000; Bjorksten, Sepp et 
al. 2001; Kalliomaki, Kirjavainen et al. 2001; Sjogren, Jenmalm et al. 2009). 
 
Kalliomaki et al. monitored 76 high-risk infants during their first year of life. Children 
in which atopy developed had a distinct bacterial fatty acid profile in their faeces at 
the age of 3 weeks. Furthermore atopic infants had lower numbers of Bifidobacteria 
and an increased amount of Clostridia (Kalliomaki, Kirjavainen et al. 2001; Penders, 
Stobberingh et al. 2007). 
A further study had partially contrary results. The number of Clostridia was 
decreased in infants with eczema in comparison to healthy subjects. It must be 
pointed out that this study quantified Clostridium lituseburense subgroup and 
Clostridium histolyticum subgroup whereas the previous study just included 
Clostridium hystolyticum subgroup. Anyhow both studies have in common a lower 
amount of Bifidobacteria in infants with eczema. The amount of lactic acid bacteria 
was higher than in healthy subjects (Mah, Bjorksten et al. 2006; Penders, 
Stobberingh et al. 2007). 
 
In a study which was part of the National Asthma Campaign Manchester Asthma and 
Allergy Study (NACMAAS) the intestinal microbiota of patients with recurrent wheeze 
was compared with that of healthy individuals. No differences were detected in the 
faecal composition of healthy subjects (Murray, Tannock et al. 2005; Penders, 
Stobberingh et al. 2007). A further study which was part of NACMAAS investigated 1-
year-old sensitized wheezy infants. Results showed that they had significant 
increased serum IgG levels against C. difficile in comparison to healthy infants 
(Woodcock, Moradi et al. 2002; Penders, Stobberingh et al. 2007). 
 
Another study concluded that patients with allergic rhinitis were more often IgG-
seropositive to intestinal bacterial pathogens like Clostridium difficile compared to 
healthy participants (Linneberg, Ostergaard et al. 2003; Penders, Stobberingh et al. 
2007). 
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Faecal samples of 957 infants were investigated in the KOALA Birth Cohort study. 
The infants were monitored for the development of atopic symptoms.  Colonisation 
with C. difficile was associated with a higher susceptibility for developing eczema and 
colonisation with E.coli was associated with eczema as well, even though in a 
concentration dependent manner (Penders, Stobberingh et al. 2007; Penders, Thijs 
et al. 2007). 
In a cross sectional study with two year old Estonian as well as Swedish children, the 
colonisation of bacteria in the gut was assessed of healthy and allergic children. The 
amount of Lactobacilli was decreased in allergic children.  Furthermore the amount of 
Staphylococcus aureus was increased in allergic children from Sweden and 
Coliforms were increased in allergic children from Estonia (Bjorksten, Naaber et al. 
1999; Penders, Stobberingh et al. 2007). Because investigators could not figure out if 
the allergy was first, or the changed composition of bacteria in the intestine, they 
conducted a further study with Swedish and Estonian children, in whom they 
collected faecal samples during the first year of life, and the children were clinically 
monitored until the age of two. Results showed that infants who developed allergy 
had a diminished amount of Bifidobacteria in the first year of life in comparison to 
healthy children (Bjorksten, Sepp et al. 2001; Penders, Stobberingh et al. 2007). 
Additionally the allergic infants had at the age of one year a decreased colonisation 
with Bacteroides (Bjorksten, Sepp et al. 2001; Songjinda, Nakayama et al. 2007). 
This result is contradictory to a pilot study from Songjinda et al. in which faecal 
samples of allergic and non-allergic infants were collected in their first 5 postnatal 
days and at the age of 1 and 2 months. Children who developed allergy by their 
second birthday had significant increased amounts of Bacteroidaceae in comparison 
to non-allergic subjects. These conflicting results may be caused by different 
sampling ages and also result due to sampling before and after weaning (Songjinda, 
Nakayama et al. 2007).  
The impact of Bacteroides is not clear until now. While Bacteroides thetaiotaomicron 
regulates intracellular downstream of TLR signalling and NF-κB activation, and 
thereby reduces inflammation (Kelly, Campbell et al. 2004; Songjinda, Nakayama et 
al. 2007), Bacteroides fragilis stimulates increased induction of TH2 cells leading to 
increased generation of inflammatory cytokines (Odamaki, Xiao et al. 2007; 
Songjinda, Nakayama et al. 2007) 
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The association between intestinal microbiota and Immunoglobulin E were 
investigated in 5 year old Estonian children in another study. Children who had 
specific IgE antibodies to food and/or inhalant allergens had higher numbers of 
Clostridia. In addition the relative share of Bifidobacteria was decreased in allergic 
children in comparison to healthy infants (Sepp, Julge et al. 2005; Penders, 
Stobberingh et al. 2007). 
 
A study from Japan compared the composition of bacteria in atopic dermatitis 
patients with healthy individuals. Bifidobacteria were reduced in atopic dermatitis 
patients and furthermore Staphylococci amounts were increased in atopic dermatitis 
patients (Watanabe, Narisawa et al. 2003; Penders, Stobberingh et al. 2007). 
 
Forty Estonian children were selected from a former larger study in which 213 
children were investigated. From these 40 children, 20 had an allergy and 20 had no 
signs of allergy during their first year of life. Of interest was the fact that allergic 
children had an earlier substitution from breast milk with cow’s milk in comparison to 
healthy infants. Due to the results of the study investigators concluded, that the 
diversity of bacteria in general was lower in allergic children compared to the control 
group.  There were no differences in the amount of Bifidobacteria between the two 
groups. Nevertheless the species of Bifidobacteria varied between the two groups. 
Bifidobacterium adolescentis occurred primarily in the faeces of allergic children, 
Bifidobacterium catenulatum and Bifidobacterium pseudocatenulatum were more 
frequent in non-allergic children (Stsepetova, Sepp et al. 2007). These results are 
equal to the results from He et al and Ouwehand et al. (He, Ouwehand et al. 2001; 
Ouwehand, Isolauri et al. 2001; Stsepetova, Sepp et al. 2007). By isolating B. 
adolescentis strains from allergic infants, investigators discovered that this bacterium 
do not adhere well on the human mucus cell wall, which might be an association to 
the aberrant immune response (He, Morita et al. 2002; Stsepetova, Sepp et al. 
2007). Furthermore this bacterium species induces proinflammatory cytokines like IL-
6, IL-12, and tumornecrosis factor-α, but can not activate regulatory cytokines like IL-
10 (Kramer, Sutherland et al. 1995; He, Morita et al. 2002; Stsepetova, Sepp et al. 
2007). In contrast B. bifidum, B. longum and B. catenulatum/pseudocatenulatum 
trigger the production of IL-10 (Young, Simon et al. 2004; Stsepetova, Sepp et al. 
2007). 
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In a study from Gore et al. infants at the age of 3 and 6 months were investigated. 
Infants had either eczema or were healthy.  Results showed no significant 
differences of Bifidobacteria in eczema patients in comparison to the control group. 
Bifidobacterium bifidum occurred especially in the faeces of breast fed infants 
whereas Bifidobacterium pseudocatenulatum was significantly increased in the 
faeces of non-breast fed infants. In infants with eczema Bifidobacterium 
pseudocatenulatum occurred more often than in healthy infants. Nevertheless the 
prevalence of the amount of Bifidobacterium bifidum significantly did not differ 
between the both groups (Gore, Munro et al. 2008). 
In a study from Young et al. the Bifidobacterial composition between infants from 
Ghana, United Kingdom and New Zealand were compared. Bifidobacterium infantis 
was present in all infants from Ghana, whereas none of the children from the United 
Kingdom or New Zealand harboured these species. The infants from the United 
Kingdom and New Zealand had 1 or more of the species B. bifidum, B. longum, B. 
adolescentis, B. pseudocatenulatum. The prevalence for atopic diseases is in Ghana 
is in contrast to the other countries very low. The authors concluded, that, B. infantis 
might play an important role because B infantis is in contrast to other species of 
Bifidobacterium not induced in the Th2 driven immune response, in contrast to B. 
bifidum, B. longum, B. adolescentis and B. pseudocatenulatum (Young, Simon et al. 
2004; Gore, Munro et al. 2008). 
 
In a Finnish case control study the microbiota in the faeces was compared between 
seven allergic breast fed infants with that of six healthy breast-fed infants. Results 
demonstrated that Bifidobacterium adolescentis occurred more often in allergic 
children, whereas Bifidobacterium bifidum was more common in healthy infants 
(Ouwehand, Isolauri et al. 2001; Penders, Stobberingh et al. 2007). 
 
The faeces of 47 Swedish children were investigated at 1 week, 1 month and or 2 
months of age and the children were followed until they reached their fifth birthday. 
16 developed allergy during the first 5 five years, whereas 31 stayed healthy the 
entire study period. Results showed the fecal samples from healthy individuals had 
higher amounts of Bifidobacterium adolescentis and Lactobacilli I group 
(Lactobacillus rhamnosus, L. casei, L. paracasei) than children who developed atopic 
disease. The increased amount of B. adolescentis in early childhood in healthy 
 76   
individuals is a contrary result to He et al. who concluded that Bifidobacterium 
adolescentis occurred more often in allergic children (He, Ouwehand et al. 2001; 
Sjogren, Jenmalm et al. 2009). Explanation of the authors might be the time window 
which means, that just very early in life bacteria have an impact on the development 
of the immune system (Garn and Renz 2007; Sjogren, Jenmalm et al. 2009). 
 
A further study from Japan investigated faecal samples from 11 adult atopic 
dermatitis patients and 14 healthy individuals. The amount of Enterobacteriaceae 
was significantly increased in AD patients in comparison to healthy subjects 
(Matsumoto, Ohishi et al. 2004; Penders, Stobberingh et al. 2007). 
 
Allergic children seem to have increased amounts of Coliforms and Staphylococci, 
whereas the numbers of Bacteroides are lowered (Bjorksten, Naaber et al. 1999; 
Sandin, Braback et al. 2009). 
 
Short chain fatty acids (SCFAs) 
SCFAs are products generated by the gut microbiota and are therefore also suitable 
to assess the composition of bacteria in the gut. 
Propionic, i-butyric, butyric, i-valeric and valeric acid were higher in non allergic one 
year old children compared to allergic. I-caproic acid and acetic acid were higher in 
allergic children (Bottcher, Nordin et al. 2000; Sandin, Braback et al. 2009). I-caproic 
acid is characteristic for the presence of Clostridium difficile (Bottcher, Nordin et al. 
2000; Shreiner, Huffnagle et al. 2008). 
In a study from Sandin et al. the faeces of 1 year old children were investigated. 
Those children who developed allergy by their fourth birthday had increased levels of 
acetic acid but decreased amounts of i-butyric, i-valeric and valeric acids (Sandin, 
Braback et al. 2009). A decline in acetic and propionic acids and an elevation of 
acids with more carbon atoms results due to the switch to an anaerobic flora (Norin, 
Midtvedt et al. 2004). Hence the results from Sandin et al. show, that children with 
allergic diseases, seem to have a reduced microbial diversity (Sandin, Braback et al. 
2009). 
 
 
 77   
Author Allergic infants Non-Allergic Infants 
(He, Ouwehand et al. 2001) Bifidobacterium adolescentis ↑ Bifidobacterium bifidum ↓ 
(Stsepetova, Sepp et al. 
2007) 
Bifidobacterium adolescentis ↑ Bifidobacterium 
pseudocatenulatum ↑ 
(Sjogren, Jenmalm et al. 
2009) 
 Bifidobacterium adolescentis ↑ 
(Ouwehand, Isolauri et al. 
2001) 
Bifidobacterium adolescentis ↑ 
Clostridium difficile ↓ 
Bifidobacterium bifidum ↑ 
(Gore, Munro et al. 2008) Bifidobacterium 
pseudocatenulatum ↑ 
 
(Young, Simon et al. 2004) Bifidobacterium infantis ↑  
(Matsumoto, Ohishi et al. 
2004) 
Enterobacteriaceae ↑  
(Bjorksten, Naaber et al. 
1999) 
Coliforms ↑ 
Staphylococci ↑ 
Enterococci ↓ 
Bifidobacteria ↓ 
Bacteroides ↓ 
(Bjorksten, Sepp et al. 2001) Bacteroides ↓ 
Clostridia ↑ 
Enterococci ↓ 
Bifidobacteria ↓ 
 
(Songjinda, Nakayama et al. 
2007) 
Bacteroides ↑  
(Bottcher, Nordin et al. 2000) Clostridia ↑  
(Kalliomaki, Kirjavainen et al. 
2001) 
Clostridia ↑ 
Bifidobacteria ↓ 
 
(Mah, Bjorksten et al. 2006) Clostridia ↓ 
Bifidobacteria ↑ 
 
(Penders, Thijs et al. 2007) Clostridium difficile ↑  
(Woodcock, Moradi et al. 
2002) 
IgG levels against Clostridium 
difficile ↑ 
 
(Linneberg, Ostergaard et al. 
2003) 
IgG levels against Clostridium 
difficile ↑ 
 
(Sepp, Julge et al. 2005) Clostridia ↑ 
Bifidobacteria ↓ 
 
(Watanabe, Narisawa et al. 
2003) 
Staphylococci ↑ 
Bifidobacteria ↓ 
 
 
Table 4. Summarized results from studies investigating the differences of microbiota in atopic 
children. 
 
 
 
 
 78   
1.2.3.4. Probiotics and Counselling 
Nutrition 
Diet may have an impact on allergy development. Dietary fats might be responsible 
for increased leukotriene and prostaglandin generation, leading to elevated likelihood 
for allergies (Shreiner, Huffnagle et al. 2008).  Dietary trans-fatty-acids were 
positively associated with childhood asthma, allergic rhinoconjunctivitis and atopic 
eczema in children (Weiland, von Mutius et al. 1999; Shreiner, Huffnagle et al. 2008). 
In a further study, increased fat intake in adult men showed increased susceptibility 
for asthma (Strom, Janzon et al. 1996; Shreiner, Huffnagle et al. 2008). 
But the type of fat seems to indeed play a role. Polyunsaturated fatty acids affect the 
integrity of the intestinal epithelium. They regulate the tight junction permeability 
(Usami, Muraki et al. 2001). Additionally the growth and adhesion of probiotics to 
mucus and epithelial cells is alleviated (Kankaanpaa, Salminen et al. 2001; Isolauri, 
Kalliomaki et al. 2008). The immune function is among others regulated by dietary 
long-chain polyunsaturated fatty acids. Especially n-3 polyunsaturated fatty acids 
seem to have anti-inflammatory properties, due to their function to inhibit the release 
of arachidonic acid.  Arachidonic acid is released by membrane phospholipids and 
produces pro-inflammatory eicosanoids (Whelan 1996; Isolauri, Kalliomaki et al. 
2008). Nevertheless in several studies consumption of fish or supplementation of fish 
oil had no effect on asthma or atopic eczema (Woods, Thien et al. 2002; van Gool, 
Zeegers et al. 2004; Isolauri, Kalliomaki et al. 2008). 
Vitamin A has a crucial role indeed. It inhibits IgE production in mouse peripheral 
blood mononuclear cells in case of allergic disease (Worm, Herz et al. 2001; Isolauri, 
Kalliomaki et al. 2008).  Furthermore it suppresses generation of Interferon-γ, IL-4 
and increases mucosal IgA, which protects the mucosal surface (Albers, Bol et al. 
2003). The activation of arachidonic acid cascade can also be changed due to 
Vitamin A supplementation inhibiting prostaglandin E2 generation in vitro (Halevy and 
Sklan 1987; Isolauri, Kalliomaki et al. 2008). 
A study from Italy came to the conclusion that high consumption of vegetables might 
be preventive for asthma (La Vecchia, Decarli et al. 1998; Shreiner, Huffnagle et al. 
2008).  In antioxidant supplementation different results occurred. One study from 
Martindale et al. concluded that, Vitamin C supplementation in prenatal women 
increased the atopic risk for infants whereas Vitamin E supplementation lowered the 
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risk (Martindale, McNeill et al. 2005; Shreiner, Huffnagle et al. 2008). Nevertheless a 
separate study identified increased Vitamin C in breast milk as a preventive agent for 
atopic diseases in infants. Notably was that Vitamin C as part of the diet occurred in 
breast milk in opposition to Vitamin C as a supplement (Dubos 1971; Fanaro, Chierici 
et al. 2003; Shreiner, Huffnagle et al. 2008). 
Laitinen et al. assessed the impact on diet and the effect of prenatal probiotic 
administration until the fourth year of life. Children with Atopic eczema who had 
prenatal probiotic administration and additionally consumed higher amounts of 
retinol, calcium, zinc and protein and lesser amount of ascorbic acid were less 
susceptible for atopic eczema development (Laitinen, Kalliomaki et al. 2005). 
 
Probiotics 
The treatment with probiotics seems to have only an impact in early infancy when the 
immune responses are still developing. Hence, in studies with older individuals with 
whom sensitization is already established, probiotics do not seem to have an effect. 
Due to the fact, that one probiotic strain is not sufficient to alter the diverse 
composition of bacteria in the gut, investigators assume prebiotics might be 
beneficial to stimulate the growth of Bifidobacterium and Lactobacilli (Prescott and 
Bjorksten 2007). Nevertheless alterations in the gut microbiota due to probiotics 
reduced the risk for atopic disease (Mai and Draganov 2009). 
At the moment contradictory results exist. While Kalliomaki et al. and Kukkonen et al. 
concluded that probiotic administration at the age of 2 years has a preventive effect 
for eczema, Taylor et al. and Kopp et al. gathered that probiotic administration had 
no impact (Kalliomaki, Salminen et al. 2001; Kukkonen, Savilahti et al. 2007; Taylor, 
Dunstan et al. 2007; Kopp, Hennemuth et al. 2008; Niers, Martin et al. 2009).  
 
In several studies the supplementation of specific probiotics alludes to have a 
positive effect. Lactobacillus GG and Bifidobacterium lactis Bb-12 showed to reduce 
allergic disorders in atopic children. They may influence the development, the 
microbial crosstalk as well as the composition of microbiota (Mattila-Sandholm, Blum 
et al. 1999; Isolauri, Arvola et al. 2000; Kirjavainen, Arvola et al. 2002; Gueimonde, 
Sakata et al. 2006; Stsepetova, Sepp et al. 2007). 
In a broader trial, infants with atopic dermatitis and a possible cow milk allergy 
received for one month either hydrolyzed whey formula with Lactobacillus GG or one 
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without this probiotic strain. Tumor necrosis factor-α decreased and additionally an 
alleviation of the clinical course proceeded (Majamaa and Isolauri 1997; Isolauri, 
Kalliomaki et al. 2008). A separate investigation conducted an experiment with 
infants who manifested atopic eczema during exclusive breastfeeding. Administration 
over 6 months with Lactobacillus GG or Bifidobacterium lactis was simultaneous with 
hydrolyzed whey formula feeding. A control group without a probiotic strain and only 
hydrolyzed whey formula feeding indeed existed. The probiotic group had a reduction 
of soluble CD4 concentration in serum and a decline of eosinophilic protein X in urine 
after 2 months with probiotic administration (Isolauri, Arvola et al. 2000; Isolauri, 
Kalliomaki et al. 2008). 
Lahtinen et al. conducted a study with 122 mothers who either received Lactobacillus 
rhamnosus GG or placebo during pregnancy. Results demonstrated that the infants 
at 90 days of age from the mothers receiving the probiotic strain had a higher 
colonisation with Bifidobacterium longum group in comparison to controls. The 
investigators concluded that an administration with probiotics in late state of 
pregnancy can have a positive impact on the development of the intestinal microbiota 
in infants.  Remarkable was the observation that in the probiotic group it did not 
matter if infants were born by vaginal delivery or caesarean section. In contradiction 
to the placebo group in whom, the type of delivery did make a difference. In this 
group caesarean section infants had increased amounts of Bifidobacterium 
adolescentis and decreased amounts of B. longum (Lahtinen, Boyle et al. 2009). 
 
Niers et al. assessed probiotic administration in pregnant mothers followed by 
administration of neonates in their first 12 months of life, who were a risk group for 
allergic diseases. Bifidobacterium bifidum W23, Bifidobacterium infantis W52 and 
Lactobacillus lactis W58 made up the probiotic supplement. Results showed that the 
neonates who received probiotics were higher colonized with Lc. Lactis during their 
first 3 months of life. Additionally the probiotic group had a decline in IL-5 generation 
in vitro. Although the amounts of Bifidobacterium spp. were increased in all 
participants, qualitative differences occurred between the two groups. While 
Bifidobacterium bifidum occurred in all probiotic infants, just half of the placebo group 
possessed this strain. The appearance of B. bifidum in half of the placebo group is 
explained by the authors due to lactation in these children wherefore they were 
colonized with this bacterium as well. In general it was observable that the infants 
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who received probiotics had a significant risk reduction of parenteral eczema during 
the first 3 months of life. The effect continued until the age of 2 years but it decreased 
with age. The authors concluded that prenatal probiotic treatment might be 
necessary to avoid the development of atopic eczema (Niers, Martin et al. 2009). 
 
Administration with B. catenulatum/pseudocatenulatum may certainly have a 
relieving effect in allergic diseases, if they are used as probiotics (Stsepetova, Sepp 
et al. 2007). 
 
In another trial children with moderate to severe eczema were either treated with 
Lactobacillus fermentum VRI-033 PCC or with a placebo. Results showed a 
significant decline of eczema scores in the probiotic group (Weston, Halbert et al. 
2005; Isolauri, Kalliomaki et al. 2008). Administration with probiotics pre- and 
postnatally over 6 months in 156 children who were susceptible for atopic disease led 
to a  reduction of atopic eczema in later infancy, in comparison to a control group 
(Kalliomaki, Salminen et al. 2001; Kalliomaki, Salminen et al. 2003; Isolauri, 
Kalliomaki et al. 2008). 
 
A study with nineteen adults between 18 and 45 years of age who suffered from 
allergic rhinitis was conducted. For two weeks the participants received either a 
probiotic drink comprising of Lactobacillus casei Shirota or a placebo. Results 
demonstrated a significant decline of allergy related cytokines like IL-5, IL-6 and IFN-
γ generation in the probiotic group. Additionally the IgE levels decreased whereas the 
IgG levels increased in the probiotic group. Therefore investigators concluded that a 
supplementation with probiotics might be beneficial in alleviating the symptoms of 
allergic rhinitis (Ivory, Chambers et al. 2008). 
 
1.2.3.5. Modern Molecular Findings, Probiotics 
Studies pointed out that the most important risk reduction for eczema development 
should be implemented in the first year of life (Niers, Martin et al. 2009). Perinatal 
probiotic administration influences the bacterial colonisation and has therefore an 
impact on the development of the infant’s immune system. By the impact on dendritic 
cells, the T-cell differentiation is affected leading to generation of T regulatory cells 
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(Smits, Engering et al. 2005; Niers, Martin et al. 2009). Probiotic supplementation led 
in a human study in vitro to an increased generation of IL-10, which is a regulatory 
cytokine (Lammers, Brigidi et al. 2003; Prescott and Bjorksten 2007). 
 L. paracasei has impact on the development of CD4(+) T cells which produce TGF-β 
and IL-10, while it inhibits the secretion of cytokines from Th1 and Th2 cells (von der 
Weid, Bulliard et al. 2001; Penders, Stobberingh et al. 2007). Lactobacillus reuteri 
and Lactobacillus casei foster the monocyte-derived dendritic cells, whereby the Treg 
cells are enhanced to increase the IL-10 generation (Smits, Engering et al. 2005; 
Penders, Stobberingh et al. 2007). Nevertheless not all Lactobacilli affect dendritic 
cells which are capable for the production of T regulatory cells. L. plantarum 
appeared not to be capable (Smits, Engering et al. 2005; Prescott and Bjorksten 
2007). 
Bifidobacterium adolescentis fosters the production of TNF-α, IL-6, and IL-12 which 
are pro-inflammatory cytokines, but it can not induce the production of IL-10 which 
would have a regulatory function (Kramer, Sutherland et al. 1995; He, Morita et al. 
2002; Stsepetova, Sepp et al. 2007). 
B.bifidum, B.longum, and B.catenulatum/pseudocatenulatum produce the regulatory 
cytokine IL-10 (Young, Simon et al. 2004; Stsepetova, Sepp et al. 2007). 
In peripheral blood mononuclear cells Bifidobacterium genomic DNA induced the IL-
10 secretion in vitro (Lammers, Brigidi et al. 2003; Penders, Stobberingh et al. 2007) 
 
IgA production in the intestine is influenced by the microbiota as well. The B cells and 
effector T cells which generate IgA, mature in the mucosa of the gut. After maturation 
they migrate to the distal mucosa sites in the respiratory tract. This is an example of 
how the gut microbiota impacts Th1 responses and IgA generation (Vancikova, 
Lodinova-Zadnikova et al. 2003; Pohjavuori, Viljanen et al. 2004; Prescott, Dunstan 
et al. 2005). 
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Figure VII. Immunologic pathways affected by probiotics. 
(Prescott and Bjorksten 2007) 
 
 
 
The allergic response is caused by T-helper type 2 (Th2) lymphocytes which are 
responsible for the generation of IL-4, IL-5, and IL-6. These cytokines foster the IgE 
production (Foley and Hamid 2006; Ivory, Chambers et al. 2008). 
Due to early probiotic administration, an increased colonisation with Lactobacillus 
lactis was observed, which was accompanied by a decline in cytokine production. In 
blood cultures at 3 months of age a lowered IL-5 and IL-13 generation in vitro was 
observed. Additionally the eczema incidence was reduced. At the same time it did 
not have an impact of high-risk children for atopic eczema (Niers, Martin et al. 2009). 
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Figure VIII. Production of cytokines in whole blood cultures at age 3 months. 
Whole blood cultures were left unstimulated (medium) or stimulated with anti CD2/anti CD28 
monoclonal antibody, or Phytohemgglutinin (PHA). Supernatants were collected at 48 h and 72 h and 
cytokines were measured by a multiplex assay (Luminex). (A) Anti CD2/CD28 48 h; (B) Anti 
CD2/CD28 72 h. Data represent mean -+ SEM. *P < 0.05.  
(Niers, Martin et al. 2009) 
 
 
 
IL-4, IL-5, IL-13 promote IgE production and are generated by Th2 cells (Rautava, 
Kalliomaki et al. 2005).  In a study from Ivory et al. treatment with Lactobacillus casei 
Shirota led to a decline in the production of IL-5, IL-6 and IFN-γ. The IgE amounts 
were higher in the placebo group in comparison to the probiotic group whereas, the 
IgG amounts were lower (Ivory, Chambers et al. 2008). Lactobacillus rhamnosus 
strain GG suppresses lymphocyte proliferation by generation of proteases and lowers 
the generation of IL-4 (Sutas, Hurme et al. 1996; Sutas, Soppi et al. 1996; Isolauri, 
Kalliomaki et al. 2008). Lactobacillus casei inhibited the IgE responses in a murin 
model of food allergy (Shida, Takahashi et al. 2002; Isolauri, Kalliomaki et al. 2008). 
An in vitro study with blood mononuclear cells demonstrated that Bacteroides fragilis 
is responsible for an increased Th2 production, which produced IL-6 and a lowered 
Th1 production, which is responsible for IFN-γ and IL-12 generation in comparison 
with Bifidobacteria (Odamaki, Xiao et al. 2007; Songjinda, Nakayama et al. 2007). 
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The Lipopolysaccharides from Enterobacteriaceae have proinflammatory effects via 
the Toll like receptor 4 pathway. Bacteroides fragilis has this function indeed, 
however it is 100-1000 fold lower (Mancuso, Midiri et al. 2005; Songjinda, Nakayama 
et al. 2007). Bacteroides thetaiotaomicron reduces inflammation by down regulation 
of TLR signalling and NF-κβ induction (Kelly, Campbell et al. 2004; Songjinda, 
Nakayama et al. 2007). 
 
 
1.2.4. Diarrhea and Constipation 
1.2.4.1. Clinical Picture 
Viral infections, parasites or bacterial toxins can lead to gastroenteritis which is 
characterized by diarrhea (Wilson 2005). Without treatment it can have life-
threatening consequences in malnourished or ill individuals (Alam and Ashraf 2003).  
 
1.2.4.1.1. Travellers Diarrhea 
Diarrhea is the most common health problem for travellers. 20-70% of the travelling 
population are affected. Of course several factors influence its susceptibility and the 
travel destination is certainly crucial (Castelli, Saleri et al. 2006). 
In most cases E.coli is the common agent for the infection. In addition other bacterial 
agents like Campylobacter jejuni, Salmonella spp., Shigella spp., Aeromonas 
hydrophila, Plesiomonas shigelloides and non choleric vibrios are determinative in 
diarrhea development. Viruses can definitely have an impact such as, Rotaviruses, 
Calciviruses and Enteroviruses. Protozoa can also be detrimental (Castelli, Saleri et 
al. 2006). 
 
1.2.4.1.2. Antibiotic-Associated Diarrhea 
5-30% of patients have to face an antibiotic associated diarrhea which lasts up to two 
months (Wistrom, Norrby et al. 2001).Treatment with antibiotics seems to disrupt the 
ecological balance which can be the cause for diarrhea (Nord, Bergan et al. 1986). 
Furthermore it leads to overgrowth of one species and an antibiotic resistance of 
pathogens or commensal bacteria is indeed possible (Lepage, Seksik et al. 2005). 
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1.2.4.1.3. Infants Diarrhea 
The UNICEF has reported that diarrhea accounts for 1.5 million deaths of children 
annualy, under the age of 5 (UNICEF 2009). 
 
1.2.4.1.4. Diarrhea in Elderly 
Elderly people are a risk group because they are hospitalized twice as frequent as 
younger people, have to stay twice as long and have double the treatment with drugs 
in comparison to younger individuals (Bartosch, Fite et al. 2004). Antibiotic treatment 
is more frequent and is therefore the chief cause for alterations of the intestinal 
microbiota (Sullivan, Edlund et al. 2001). 
 
1.2.4.1.5. Constipation 
Constipation is very common in modern societies and especially elderly are 
frequently affected. Constipation is more prevalent in elderly who live in nursing 
homes and hospitals in comparison to elderly living in the community. 80% of 
residents in nursing homes suffer from constipation. Changes in food habits, the lack 
of exercise and the loss of privacy or personality are some factors which contribute to 
the development of constipation (An, Baek et al.).  The treatment of medication is a 
further reason for the development of constipation (An, Baek et al.; Frank, Schmier et 
al. 2002). The large intestine is affected. Constipation is characterized by low 
defecation frequency, irregular stool expulsion, painful and strained defecation, hard 
and dry stool consistency, passing of abnormally small stools and a feeling of 
incomplete rectal defecation (An, Baek et al.; Bosaeus 2004). 
 
1.2.4.2. Therapy 
1.2.4.2.1. Travellers Diarrhea 
In healthy individuals it is self limiting, whereas in risk groups, like young children, 
elderly, and ill persons it can be more difficult. Hospitalization or at least bed rest 
might be necessary (Ericsson 2003; Castelli, Saleri et al. 2006). 
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1.2.4.2.1.1. Preventative treatment with Antibiotics 
Treatment with antibiotics showed in several studies a preventive effect. Several 
studies identified antibiotics like neomycin (Kean 1986), doxycycline (Sack, Kaminsky 
et al. 1978), trimethoprim-sulfamethoxazole (DuPont, Evans et al. 1982), and 
fluoroquinolones (Parry, Howard et al. 1994) as preventive drugs for traveller’s 
diarrhea (Castelli, Saleri et al. 2006). Du Pont et al. conducted a trial with US 
students travelling to Mexico receiving rifaximin. Results showed that 72% were 
protected against traveller’s diarrhea (DuPont, Jiang et al. 2005; Castelli, Saleri et al. 
2006). The efficacy of the treatment depends on the type of antibiotic as well as the 
area of destination (Castelli, Saleri et al. 2006). 
However this kind of prevention is not innocuous. Antibiotics have several adverse 
effects, only the antibiotic rifaximin seems to be well tolerated with little adverse 
effects (Ericsson and DuPont 2005; Castelli, Saleri et al. 2006). Nevertheless, due to 
the fact that traveller’s diarrhea is a self-limiting disease it is disputable if antibiotic 
treatment as prevention is reasonable (Castelli, Saleri et al. 2006). 
 
1.2.4.2.1.2. Treatment of Diarrhea 
If someone suffers from diarrhea, rehydration should be the first attempt to alleviate 
the symptoms. Symptomatic therapy and antimicrobial therapy are further 
possibilities for treatment. 
Rehydration 
Rehydration is an important issue if someone suffers from diarrhea. Due to the 
restoration of hydric and electrolytic balance, possible complications might be 
avoided. Oral rehydration solutions contain glucose, and thereby facilitate the 
absorption of sodium, water and bicarbonates. The rehydration is also important to 
reconstitute the milieu which is acidified due to diarrhea (Castelli, Saleri et al. 2006). 
 
Figure IX. Composition of WHO/UNICEF and home-made oral rehydration solutions. 
(Scarpignato and Rampal 1995; Castelli, Saleri et al. 2006) 
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Symptomatic Therapy: 
Symptomatic therapy is needed to reduce the number of unformed stools. Most 
common medications are bismuth subsalicylate preparation and loperamide, which 
have an antisecretory effect (Scarpignato and Rampal 1995).  
Antibiotic Therapy: 
While mild cases of traveller’s diarrhea should only be treated with rehydration or 
eventually a symptomatic therapy, severe cases might need antibiotic treatment. 
Nevertheless it should be considered that antibiotics have adverse effects and 
thereby should be used carefully. Trimethoprim-Sulfamethoxazole seems to be the 
first choice, followed by Doxycycline. Fluoroquinolones and Azithromycin are a 
further antibiotic choice. In uncomplicated infectious diarrhea, rifaximin seems to be 
the best treatment due to it’s poor absorption ability (Castelli, Saleri et al. 2006). 
 
1.2.4.2.2. Treatment of Antibiotic-Associated Diarrhea 
The standard treatment for Clostridium difficile infection is Vancomycin or 
Metronidazole. The response rate for Metrondiazole is declining and therefore 
alternative therapies might be a major interest in health care systems (McFarland, 
Beneda et al. 2007). 
 
1.2.4.2.3. Treatment of Constipation 
Treatment with laxatives is the common therapy for patients suffering from 
constipation. This treatment is well established and safe, however it is not helpful for 
all patients and therefore it is necessary to establish other possibilities (Chmielewska 
and Szajewska; Bongers, Benninga et al. 2009). 
 
1.2.4.3. Composition and Differences to Normal Microbiota 
In healthy individuals the human gut microbiota protects the gastrointestinal tract 
from enteric infections (Sekirov and Finlay 2009). 
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1.2.4.3.1. Antibiotic Associated Diarrhea 
Sekirov et al conducted a trial in which antibiotic treatment led to a significant 
increase of the inflammatory response to Salmonella enterica infection (Sekirov and 
Finlay 2009). The chief cause for antibiotic-induced diarrhea (AAD) is Clostridium 
difficile which is responsible for 10-25% of all cases of AAD and for nearly all cases 
of pseudomembranous colitis (Bartlett 1987). Clostridium difficile is known as a 
causative agent of AAD since 1978 (Bartlett, Moon et al. 1978). Two toxins are 
produced by Clostridium difficile, which are responsible for the mucosal damage and 
inflammation in the colon (Hogenauer, Hammer et al. 1998). 
Further bacteria which might be involved in antibiotic-associated diarrhea are 
C.perfringens, Staphylococcus aureus, Candida spp., Klebsiella oxytoca and 
Salmonella spp. (Hogenauer, Hammer et al. 1998). 
 
1.2.4.3.2. Infants Diarrhea 
Alterations in the composition of gut microbiota appear during diarrhea. The amount 
of fecal bacteria especially of Bacteroides-Prevotella-Porphyromonas group, E. 
rectale, L. acidophilus and F. prausnitzii group are reduced during acute diarrhea in 
contrast to periods of a normal health state (Balamurugan, Janardhan et al. 2008). 
 
1.2.4.3.3. Diarrhea in Elderly 
Especially Bifidobacteria, Lactobacilli and Bacteroides are crucially reduced which 
enables pathogens to enforce (Sullivan, Edlund et al. 2001). 
 
1.2.4.3.4. Constipation 
Patients suffering from constipation have a different composition of microbiota in 
comparison to healthy individuals (Chmielewska and Szajewska; Salminen and 
Salminen 1997; Zoppi, Cinquetti et al. 1998). Different species of Clostridia and 
Bifidobacteria and Enterobacteriaceae seem to be increased in comparison to 
healthy individuals (Chmielewska and Szajewska; Picard, Fioramonti et al. 2005).   
 
 90   
1.2.4.4. Probiotics and Counselling 
1.2.4.4.1. Alimentary Precautions in Traveller Diarrhea 
Due to changed food consumption during travel time humans are confronted, mostly 
with bacterial agents which they are not used to, and therefore the mucosal immunity 
is lacking, which then leads to altered bacterial colonization, in addition to 
inflammation and finally to diarrhea. Hence the general advisement exists: “boil it, 
cook it, peel it, or forget it”. Fresh vegetables and fruits should be washed and 
peeled, raw and rare cooked food, like meat and fish should be avoided as well as 
dietary products and drinking tap water should be boiled for 3-5 minutes before 
drinking (Castelli and Carosi 1995; Castelli, Saleri et al. 2006).   
 
1.2.4.4.2. Probiotics 
In order to assess the specific functions of probiotics in the gastrointestinal tract, a 
better regime in defined clinical situations is necessary. Furthermore a mix of 
different probiotic strains with improved designed functions are urgently needed to 
reach a clinical success (Madsen 2008). 
Several strains possess the qualification to produce proteins which either degrade 
the toxins generated by Clostridium difficile or increase the immune response to 
Clostridium difficile toxins A and B (Kekkonen, Lummela et al. 2008). 
 
1.2.4.4.2.1. Probiotics in Diarrhea 
Lactobacillus rhamnosus was adequate for treating rotaviral diarrhea in a double 
blind study. Treatment with Lactobacillus rhamnosus reduced the morbidity due to 
shortening the time of dehydration and hence the time of intravenous rehydration 
was diminished (Goossens, Jonkers et al. 2003).  
Probiotics are suitable as a prophylaxis for travelling diarrhea. A Meta-analysis from 
Mc FARLAND (2007) summarised 12 studies with a total of 4709 probands about 
probiotic supplementation. It reasoned that probiotics can significantly reduce the risk 
to contract diarrhea by about 15%. Lactobacillus acidophilus combined with 
Bifidobacterium bifidum or Saccharomyces boulardii, indicate the best effects for a 
prophylaxis (Schulze, Sonnenborn et al. 2008). 
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Yet currently conflicting results in studies exist (Katelaris, Salam et al. 1995) and a 
positive impact has just been proven by Saccharomyces boulardii (D'Souza, 
Rajkumar et al. 2002) and Lactobacilus GG (Marteau, de Vrese et al. 2001; Castelli, 
Saleri et al. 2006).  Although probiotics are safe, the data is not sufficient enough to 
use them as a solely preventive therapy (Castelli, Saleri et al. 2006). 
 
1.2.4.4.2.2. Probiotics in Infant’s Diarrhea 
A prevention study in a child care centre in Israel was accessed in order to assess 
the impact of Bifidobacterium lactis or Lactobacillus reuteri strain in comparison to a 
placebo in diarrhea. Due to the probiotic treatment, the amount of days with diarrhea 
was shortened although only Lactobacillus reuteri showed significant effects 
(Bergonzelli, Blum et al. 2005; Weizman, Asli et al. 2005). Lactic acid bacteria even 
when belonging to the same species have different impacts on diarrhea. While L. 
rhamnosus GG reduced the duration of diarrhea and the quantity of watery stools, L. 
rhamnosus strain Lactophilus had no impact (Majamaa, Isolauri et al. 1995; 
Bergonzelli, Blum et al. 2005). In a study of 230 hospitalized Bangladeshi children, 
due to acute gastroenteritis, administration with L.paracasei NCC2461 was 
assessed. The treatment had no effect on the rota-virus associated diarrhea but in 
children with non-rotavirus diarrhea the duration time was reduced. Furthermore the 
stool output became reduced and stool frequency and oral rehydration solution could 
be reduced indeed (Bergonzelli, Blum et al. 2005; Sarker, Sultana et al. 2005). In 
Allgeria the consumption of yoghurt containing L.delbrueckii and S. thermophilus 
significantly reduced the duration of diarrhea and reduced the number of watery 
stools in comparison to children which were fed with milk formula (Boudraa, Touhami 
et al. 1990; Boudraa, Benbouabdellah et al. 2001; Bergonzelli, Blum et al. 2005). 
Another study with malnourished Indian children could not reach such positive results 
(Bhatnagar, Singh et al. 1998). Lactobacillus GG seems to have an impact in 
European children while in children from developing countries it seems to have no 
effect (Bergonzelli, Blum et al. 2005). Separate studies with Finnish infants (Isolauri, 
Juntunen et al. 1991; Kaila, Isolauri et al. 1992) as well as a study with Italian infants 
(Guarino, Canani et al. 1997) and a further study with an increased Euopean 
population (Guandalini, Pensabene et al. 2000) showed a positive effect of 
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Lactobacillus GG, by shortening the duration time of diarrhea as well as reducing the 
number of diarrheal stools (Bergonzelli, Blum et al. 2005). 
In studies with children from developing countries no positive impact could be 
achieved with probiotic administration (Raza, Graham et al. 1995; Costa-Ribeiro, 
Ribeiro et al. 2003; Salazar-Lindo, Miranda-Langschwager et al. 2004; Bergonzelli, 
Blum et al. 2005).  
Prevention trials 
Lactobacillus GG was administered to 80 children from Poland, which led to a 
significant reduction of incidence rate in diarrhea but the treatment had no impact on 
the duration of diarrhea (Szajewska, Kotowska et al. 2001; Bergonzelli, Blum et al. 
2005). In comparison to this study, a study from Peru with 200 children found no 
positive impact due to Lactobacillus GG treatment (Oberhelman, Gilman et al. 1999; 
Bergonzelli, Blum et al. 2005). Similar results gained the investigators from a finish 
study with 570 children in whom the treatment with L.rhamnosus GG had no effect on 
diarrhea (Hatakka, Savilahti et al. 2001; Bergonzelli, Blum et al. 2005).  
 
The above mentioned studies showed conflicting results. While in European 
countries Lactobacillus seems to have a positive impact on diarrhea, this is not 
observable in developing countries. While in developing countries bacterial 
pathogens seem to play an important role, rotavirus is crucial for diarrhea 
development in industrialized countries. On the one hand this could be an 
explanation why in the studies above, probiotic treatment did not have an impact in 
developing countries. Otherwise in the studies, the L.paracasei treatment was only 
efficient in non-rotavirus diarrhea which led to the conclusion by Bergonzelli et al. that 
a combination of L.paracasei NCC2461 and L.rhamnosus GG might be helpful 
against viral and bacterial diarrhea (Bergonzelli, Blum et al. 2005). 
 
1.2.4.4.2.3. Probiotics and Prebiotics in Constipation 
Probiotics 
A trial was implemented on elderly from a nursing home suffering from chronic 
constipation. Participants received lactic acid bacteria, more precisely Lactobacillus 
acidophilus, Pediococcus pentosaceus and Bifidobacterium longum SPM1205 twice 
a day for 2 weeks. Fecal samples were collected before the trial and after the trial. 
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Results showed an increase of defecation and amount of stool defecation occurred 
due to probiotic administration. Nevertheless, the changes were not significant. 
Investigators concluded that probiotics might lead to an alleviation of symptoms and 
might therefore be used as additional treatment (An, Baek et al.). B.lactis DN-173010 
improved the colonic transit in a healthy population (Picard, Fioramonti et al. 2005) 
as well as in patients suffering from constipation (Chmielewska and Szajewska; 
Agrawal, Houghton et al. 2008). Möllenbrick and Bruckschen conducted a study with 
70 constipated patients. Patients received either E.coli Nissle 1917 or a placebo. 
Investigators found that the treatment led to a significant improvement in tolerance 
and effectiveness in the probiotic group in comparison to the placebo group 
(Chmielewska and Szajewska; Mollenbrink and Bruckschen 1994). 
In another study 140 adults suffering from constipation received two probiotics 
strains, namely E.coli Nissle 1917 and L. casei Shirota. The probiotic administration 
significantly improved stool frequency and consistency (Chmielewska and 
Szajewska; Banaszkiewicz and Szajewska 2005). 
Koebnick et al. conducted a study with 70 patients suffering from constipation. The 
probiotic group were treated with a beverage enriched with L. casei Shirota, the 
control group received a placebo beverage. Results demonstrated a significant 
improvement in severity, stool consistency, occurrence of hard stools and frequency 
of defecation (Chmielewska and Szajewska; Koebnick, Wagner et al. 2003). 
Yang et al. accomplished a study over a two week time frame with women suffering 
from constipation. Participants received either a fermented milk product enriched with 
B. lactis DN-173 010, S. thermophilus and  L. bulgaricus (experimental group) or 
acidified milk which contained non-living bacteria (control group). The experimental 
group had in comparison to the control group a higher stool frequency, only after one 
week. The defecation conditions were significantly improved as well as the stool 
consistency in the experimental group (Chmielewska and Szajewska; Yang, He et al. 
2008). 
Ouwehand et al. concluded that a combined administration with L.rhamnosus and 
Propionibacterium freudenreichii increased the defecation frequency (Chmielewska 
and Szajewska; Ouwehand, Lagstrom et al. 2002).  
In a trial from Lee et al. constipated patients and healthy subjects received either 
Streptococcus faecium combined with Bacillus subtilis, or a placebo. The trial lasted 
2 weeks. Results indicated that due to probiotic treatment an improved defecation 
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and a better bowel preparation occurred in the probiotic group in comparison to the 
placebo group (Lee, Kim et al. 2009).  
 
Prebiotics 
Lactulose and Sorbitol are besides others, nondigestible disaccharides and have a 
laxative effect. Furthermore they are regarded as safe and enhance the growth of the 
Bifidoflora. In elderly suffering from constipation administration with Galacto-
Oligosaccharides, led to an alleviation of constipation (Kaur and Gupta 2002; Roy, 
Kien et al. 2006). In general, prebiotics seem to have a beneficial impact in 
constipation therapy. Prebiotics increased stool frequency in healthy individuals 
(Hond, Geypens et al. 2000; Roy, Kien et al. 2006).  Acetate and propionate seem to 
have impact on colonic blood flow.  Due to short chain fatty acids the contractility of 
the colon is certainly increased in rats. Short chain fatty acids seem to have an 
impact on the upper gut musculature, enhance nutrient absorption by their impact on 
blood flow and fasten transit through the colon (Roy, Kien et al. 2006). 
 
1.2.4.5. Modern Molecular Findings, Probiotics, Prebiotics and Counselling 
 
1.2.4.5.1. Probiotics 
Probiotics have beneficial effects on the modulation of intestinal barrier function 
which is formed by intestinal epithelial cells and intercellular junctions. Treatment with 
E.coli Nissle 1917 fostered gene and protein expression of the tight junction molecule 
ZO-1 (Ukena, Singh et al. 2007). 
Lipopolysaccharides (LPS) are a triggering factor for inflammation. Via the toll like 
receptor 4 pathway, they induce TNF-α, IL-1 and IL-6 which are pro-inflammatory 
cytokines (Peluso, Fina et al. 2007). In an animal trial investigators came to the result 
that Bifidobacteria seem to improve the barrier function of the gut mucosa. Due to the 
increase of Bifidobacteria the translocation of bacterial LPS could be reduced 
(Riedel, Foata et al. 2006). L.paracasei subsp. Paracasei B21060 blocked the T cell 
growth and might therefore be beneficial in modulating immune response (Peluso, 
Fina et al. 2007). 
L.reureri produces a bacteriocin, namely reuterin which is effective against yeast, 
fungi, protozoa and viruses (Spinler, Taweechotipatr et al. 2008). 
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Probiotics have a positive impact for patients suffering from constipation because 
they lower the pH in the colon which leads to an increased production of short chain 
fatty acids by bacteria. Additionally a lower pH fosters the peristalsis in the colon 
(Salminen and Salminen 1997) and thereby decreases colonic transit time 
(Chmielewska and Szajewska). 
B. animalis DN-173 010 has a positive impact on transit time and is therefore 
appropriate as additional therapy for patients suffering from constipation. However it 
is just as effective in living form and not heat-treated (Chmielewska and Szajewska; 
Bouvier, Meance et al. 2001). 
 
1.2.4.5.2. Prebiotics 
Patients suffering from diarrhea seem to reach a symptom-alleviation by prebiotic 
administration. Due to the short chain fatty acid generation out of prebiotics, the 
absorption of Na+ is fostered. Oral rehydration solutions should be supplemented 
with Oligosaccharides. Short chain fatty acids increase the growth and differentation 
of certain bacteria, furthermore they up-regulate Toll like receptors and thereby 
influence the epithelial crosstalk (Forchielli and Walker 2005; Roy, Kien et al. 2006), 
additionally they stimulate production of cytokines like IL-10 and INF-γ, and foster the 
generation of polymeric IgA (Roller, Rechkemmer et al. 2004; Zapolska-Downar, 
Siennicka et al. 2004; Roy, Kien et al. 2006). Nevertheless no meaningful studies 
have been conducted with prebiotics and their impact on diarrhea until now (Roy, 
Kien et al. 2006). 
During enteral tube feeding, diarrhea is very common (Euler, Mitchell et al. 2005; 
Roy, Kien et al. 2006). Colonic atrophy and a deficit of short chain fatty acids might 
be the cause for frequent diarrhea. The short chain fatty acid deficit leads to a decline 
of anaerobes and to an increase of aerobes, which could have detrimental effects 
(Schneider, Le Gall et al. 2000; Schneider, Girard-Pipau et al. 2005; Roy, Kien et al. 
2006). Therefore enrichment of enteral formula with Fructooligosaccharides 
increased Bifidobacteria and reduced Lactobacilli and of course a 2-fold increase of 
SCFA concentrations was notable (Whelan, Judd et al. 2005; Roy, Kien et al. 2006). 
Enrichment of tube feeding with pectin led to a decrease in liquid stools and the 
formula was better tolerated (Zimmaro, Rolandelli et al. 1989; Roy, Kien et al. 2006).   
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2. DISCUSSION 
 
The aim of this work was the assessment of the impact of probiotic administration in 
patients suffering from genetic and molecular dispositions. 
Several studies in which the compositions of the gut microbiota in diverse 
dispositions were assessed are discussed in this work. Furthermore the influence of 
probiotic administration was evaluated in these studies. 
In recent years genetic and molecular dispositions increased, especially in 
westernized countries. On this account additional therapies are more than ever 
needed to get this vast increase of dispositions under control.  
The hygiene hypothesis declares that the increase of atopic diseases is associated 
with the reduced exposure of microbes in early infancy. This is due to environmental 
changes in industrialized countries. Sanitation and living conditions are improved and 
vaccination and antimicrobial therapy have their impact as well. Additionally the 
changed microbiota might be associated with the vast increase of obesity (Isolauri, 
Kalliomaki et al. 2009). 
Many questions have to be clarified before it is possible to determine if differences in 
the gut may lead to different weight in humans. It has to be determined if the 
alterations in the gut are the cause or the result for obesity. Also hormones and other 
signals and their influence on the composition of the microbiota must be regarded. 
Besides the understanding of the relative proportions of Firmicutes, Bacteroidetes 
and Archaea in mice and humans have to be elucidated. The environmental as well 
as the genetic factors of each individual must also be regarded, but also the surface-
adherent differences of the microbiota in the mucosa must be elucidated for obese 
and person who already lost weight (DiBaise, Zhang et al. 2008). 
The character and specifity of counselling concerning inflammatory bowel diseases 
has changed due to increased microbiological knowledge. Due to the fact that the 
knowledge is permanently developing, it is difficult to assess in which direction it will 
lead. 
At the moment the core microbiome attracts increased interest leading to intensive 
discussions. The consequences of the microbiome in association with the disorders 
are still waiting to be investigated. Investigations of the microbiome may lead to 
better therapeutic treatment of single disorders. 
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3. ABSTRACT 
 
The composition of microbiota seems to differ between healthy individuals and 
patients suffering from genetic and molecular disorders. Several studies have already 
been conducted to assess whether the changed microbiota may be the cause or the 
consequence of the disorders. Until now it has not been proven that the alternated 
microflora compositions are determining in disease development. Nevertheless it has 
been proven that environmental, genetic and as well as immunological factors 
influence the development of several disorders such as, allergies, obesity, 
inflammatory bowel disease, diarrhea and constipation, of which will be discussed in 
detail in this work. Several studies have already identified differences between 
microbiota in healthy individuals in comparison to patients suffering from disorders. 
The disorders have in common, that the bacterial diversity appears to be reduced 
while the bacterial load seems to be increased. 
In patients with Inflammatory bowel disease the amount of Firmicutes particularly 
Lactobacilli, Bifidobacteria and Faecalibacterium prausnitzii is lowered while the 
amount of E.coli has increased in those patients. 
In contrary to obese humans the Firmicutes concentration is increased, while the 
Bacteroidetes abundance is diminished. Some bacteria seem to extract more 
calories out of edibles compared to others, and are therefore supposed to be 
decisive in obesity development. The phyla Archaea seem to be indeed crucial, 
particularly Methanobrevibacter smithii. The combined occurrence of 
Methanobrevibacter smithii and Bacteroides thetaiotaomicron influence the energy 
extraction out of edibles.  
Allergy development is affected as well by the bacterial colonisation. Children who 
develop an allergy appear to have an increased colonisation with Clostridia, 
Enterobacteria and Staphylococcus, whereas Bifidobacteria and Lactobacilli are 
lowered in their amount in early childhood. 
Patients suffering from diarrhea or constipation have an alternated microbiota as 
well. Bifidobacteria, Lactobacilli and Bacteroides seem to be crucially reduced 
whereby potential pathogen bacteria can be enforced and consequently damage the 
gut. 
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Nutritional recommendations for specified diseases based on modern molecular 
findings are provided in this work. Due to the alternated microbiota, administration 
with probiotics might be a safe and inexpensive therapeutic target to alleviate the 
symptoms. Especially administration with Lactobacilli and Bifidobacteria seems to 
have a beneficial impact. Nevertheless there are several studies with conflicting 
results and therefore further studies are needed to aggravate this assumption. 
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4. ZUSAMMENFASSUNG 
 
Die Zusammensetzung der Mikrobiota scheint sich bei Personen mit genetischen 
und molekularen Erkrankungen individuell zu unterscheiden. Es wurden bereits 
verschiedene Studien durchgeführt, um festzustellen, ob die veränderte Mikrobiota-
Zusammensetzung die Ursache oder die Folge der Erkrankungen waren.  
Bisher konnte noch nicht bestätigt werden, dass die veränderte Zusammensetzung 
der Mikroflora für den Krankheitsverlauf entscheidend ist. Trotz allem ist bekannt, 
dass umweltbedingte, genetische, sowie immunologische Faktoren Einfluss auf den 
Krankheitsverlauf unterschiedlichster Erkrankungen wie Allergien, Adipositas, 
chronisch entzündliche Darmerkrankungen, Diarrhö und Obstipation haben. Diese 
Erkrankungen werden in der folgenden Arbeit genauer untersucht. Durch diverse 
Studien konnten bereits Unterschiede in der mikrobiellen Zusammensetzung bei 
gesunden im Vergleich zu kranken Individuen festgestellt werden. Alle Erkrankungen 
haben gemein, dass die bakterielle Diversität signifikant reduziert ist, wohingegen die 
bakteriellen Konzentrationen deutlich erhöht sind. 
Patienten, die an chronisch entzündlichen Darmerkrankungen leiden, weisen eine 
Reduktion an Firmicutes auf, vor allem Laktobazillen, Bifidobakterien, und 
Faecalibacterium prausnitzii sind vermindert, während E.coli-Gehalte bei diesen 
Patienten erhöht sind. 
Im Gegensatz dazu weisen adipöse Patienten erhöhte Firmicutes-Gehalte auf, 
während die Menge an Bacteroides reduziert ist. Manche Bakterien scheinen mehr 
Kalorien aus Lebensmitteln zu extrahieren als andere, weshalb sie von großer 
Bedeutung für die Adipositas-Entwicklung sind. Des Weiteren scheint das Phylum 
Archaea, vor allem Methanobrevibacter smithii, eine bedeutende Rolle zu spielen. 
Gemeinsames Vorkommen von Methanobrevibacter smithii und Bacteroides 
thetaiotaomicron beeinflusst die Energieextraktion aus Lebensmitteln.  
Die Entwicklung allergischer Erkrankungen steht ebenfalls in Zusammenhang mit der 
bakteriellen Kolonisation des Darmes. Kinder, die eine Allergie entwickeln, weisen 
eine erhöhte Kolonisation von Clostridien, Enterobakterien und Staphylococcus auf, 
während die Menge an Bifidobakterien und Lactobacillen in der frühen Kindheit 
reduziert ist.  
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Patienten, die von Diarrhö oder Obstipation betroffen sind, weisen ebenfalls eine 
veränderte Mikrobiota-Zusammensetzung auf. Bifidobakterien, Lactobacillen und 
Bacteroides scheinen deutlich reduziert zu sein, wodurch potentiell pathogene 
Bakterien vermehrt auftreten und damit den Darm schädigen können. 
Ernährungsempfehlungen für diese speziellen Krankheiten basieren auf modernen 
molekularen Erkenntnissen und werden in dieser Arbeit behandelt. Aufgrund der 
veränderten Mikrobiota könnte eine Behandlung mit Probiotika ein sicheres und 
billiges therapeutisches Ziel sein, um die Symptome zu mildern. Vor allem 
Laktobazillen und Bifidobakterien haben in diesem Zusammenhang besonders 
positive Auswirkungen. Allerdings gibt es viele Studien mit widersprüchlichen 
Ergebnissen, weshalb weiterer Forschungsbedarf auf diesem Gebiet gegeben ist.  
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